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Abstract
In physiological wound healing, the skin has an intrinsic capacity to heal itself and
restore its function after injury. In the case of burns, (chronic) ulcers or large scale skin
traumata, the skins' regenerative capacities might be disturbed or insuﬃcient, making
external assistance such as wound dressings or grafts necessary. Skin auto- or allografts
are well-established in the clinics, although both methods suﬀer from several drawbacks,
for instance limited donor tissue, an increased risk of inﬂammation and infection or the
need for immunomodulation.
An upcoming alternative is seen in stem cell application. Mesenchymal stem cells
(MSC) are ideal owing to their self-renewal capacity and diﬀerentiation potential. They
can be harvested from several tissues, such as bone marrow, adipose tissue or umbilical
cord blood. MSC are involved in tissue regeneration, wound healing and they secrete,
among other cytokines, hepatocyte growth factor (HGF). Importantly, HGF concentration
is enhanced in wounded areas, and its chemoattractive potential for MSC and other cell
types related to wound healing processes has been shown.
Tissue Engineering encompasses autologous or allogenic cell sources, natural or syn-
thetic biomaterials or a combination thereof as well as cytokines to restore and remodel
tissue function. In the standard approach, all components are combined ex vivo and the
hybrid is then implanted into the patient; major drawbacks of this approach are the time-
and cost-intensive in vitro steps of cell isolation, expansion and diﬀerentiation.
Our objective is the development of a delivery system which releases HGF in an ap-
propriate manner to improve wound healing in vivo. This combinatorial wound dressing
should mobilize endogenous MSC from their tissue-speciﬁc niches towards the wounded
area. We investigated three natural biomaterials for MSC recruitment in vitro and in vivo:
collagen, ﬁbrin and silk ﬁbroin with and without HGF. In vitro, HGF release kinetics from
all biomaterials were controlled over a period of seven days. A burst release of HGF after
the ﬁrst eight hours was followed by a gradual release of HGF afterwards for up to seven
days. HGF was identiﬁed as a strong chemoattractant for MSC in an in vitro model of
wound healing (scratch assay) as well as in modiﬁed models of the Boyden Chamber Assay
where MSC migrated towards HGF-loaded biomaterials. Furthermore, the HGF receptor
c-Met was shown to play a role in MSC motility and migration. In vivo, collagen and silk
ﬁbroin were tolerated well in a murine model of subcutaneous implantation and MSC were
located in and around HGF-loaded biomaterials.
Concluding, this study presents for the ﬁrst time the successful recruitment of MSC
towards HGF-loaded collagen, ﬁbrin and silk ﬁbroin scaﬀolds in vitro and in vivo. In the
future, further in vivo studies and clinical trials are necessary to prove functionality of
the developed MSC recruitment system. Patients suﬀering from chronic wounds or burns
could proﬁt from these oﬀ-the-shelf, readily available constructs.
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Zusammenfassung
Unter physiologischen Bedingungen ist die Haut in der Lage sich selbst zu regenerieren
und ihre ursprünglichen Funktionen wiederzuherstellen. In verschiedenen Fällen, wie etwa
bei chronischen Ulcera oder großﬂächigen Verbrennungen, werden die intrinsischen regene-
rativen Kapazitäten der Haut gestört, was die Notwendigkeit externer Hilfen in Form von
Wundauﬂagen oder Transplantationen bedingt. Heutzutage sind Auto- und Allotransplan-
tationen in der Klinik zwar etabliert, jedoch bergen beide Methoden mehrere Nachteile,
wie zum Beispiel limitiertes autologes Spendergewebe, ein erhöhtes Entzündungsrisiko oder
lebenslange Immunsuppression.
Eine mögliche Alternative liegt in der Anwendung von Stammzellen. Optimale Zell-
kandidaten stellen mesenchymale Stammzellen (MSC) dar, die sich durch ihr Selbst-
erneuerungs- sowie Diﬀerenzierungspotential auszeichnen. MSC können verhältnismäßig
leicht aus verschiedenen Geweben wie dem Knochenmark, Fettgewebe oder Nabelschnur-
blut isoliert werden und sind nachweislich an der Geweberegeneration sowie der Wund-
heilung beteiligt. Neben anderen Zytokinen sekretieren MSC auch den Hepatozytenwachs-
tumsfaktor (HGF), dessen Konzentration besonders in Wunden erhöht ist. In der Literatur
konnte HGF als Chemoattraktant für MSC selbst und andere Zellen, die an der Wund-
heilung beteiligt sind, nachgewiesen werden.
Um verletztes Gewebe sowie dessen Funktionen wiederherzustellen, wird das Tissue
Engineering genutzt. Der gängige Ansatz ist eine Kombination aus Zellen, Biomaterialien
und Zytokinen, die ex vivo kombiniert und im Anschluss dem Patienten implantiert werden.
Dieser Ansatz beinhaltet jedoch die Zeit- und Kosten-intensive in vitro Kultivierung und
Diﬀerenzierung der Zellen.
Ziel dieser Studie ist die Entwicklung eines Systems zur gezielten Freisetzung von
HGF zur Verbesserung der Wundheilung in vivo. Als Wundauﬂage soll dieses System die
Patienten-eigenen Stammzellen aus ihren Gewebe-speziﬁschen Nischen anlocken und zur
Defektregion dirigieren.
In Kombination mit HGF wurden die natürlichen Biomaterialien Kollagen, Fibrin und
Seidenﬁbroin in vitro und in vivo analysiert. In vitro wurde HGF in den ersten acht Stunden
stark und von Tag zwei bis Tag sieben kontrolliert graduell freigesetzt. HGF wurde als
starkes Chemoattraktant für MSC in einem in vitro Wundheilungsmodell sowie in modi-
ﬁzierten Boyden Kammer Modellen nachgewiesen. Die Migration von MSC in Richtung der
HGF-beladenen Biomaterialien konnte ebenfalls gezeigt werden. Der HGF Rezeptor c-Met
wurde als wichtig für die Zellmotilität und -migration eingestuft. Kollagen und Seiden-
ﬁbroin wurden in einem murinen Subkutanmodel gut toleriert und die Mobilisierung von
MSC in Richtung HGF konnte nachgewiesen werden.
Eine erfolgreiche Rekrutierung mesenchymaler Stammzellen in Richtung HGF-bela-
dener Kollagen-, und Seidenﬁbroin-Scaﬀolds in vitro und in vivo konnte gezeigt werden.
In der Zukunft sollten weitere in vivo, sowie klinische Studien die Funktionalität des hier
entwickelten MSC Rekrutierungssystem veriﬁzieren. So könnten Patienten mit chronischen
Ulcera oder großﬂächigen Verbrennungen von diesen gebrauchsfertigen, direkt einsatz-
bereiten Wundauﬂagen proﬁtieren.
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1 Introduction
1.1 Tissue Engineering
I shall begin at the beginning. (...) These, he waved his hand, are the in-
cubators. And opening an insulated door he showed them racks upon racks of
numbered test-tubes (...) [Huxley, 1946].
The book Brave New World written by Aldous Huxley and published for the ﬁrst time in 1932
already indicates unknowingly the groundwork of today's Tissue Engineering (TE).
Even though the ﬁeld of TE did not emerge until the 1990s, its momentous impact is
undeniable for the scientiﬁc world to date. In 1991, a patient was implanted with a tissue-
engineered synthetic polymer scaﬀold seeded with autologous chondrocytes to replace his absent
sternum, which was among the early TE approaches reviewed in the history of TE [Vacanti,
2006]. However, it was the Auriculosaurus, a mouse with a human-shaped ear made of tissue-
engineered cartilage grown on its back (Figure 1) that highly raised the public awareness and
skepticism of the newly explored ﬁeld in the late 1990s [Cao et al., 1997].
Langer and Vacanti deﬁned TE in 1993 as an interdisciplinary ﬁeld that applies the principles
of engineering and life sciences toward the development of biological substitutes that restore,
maintain or improve tissue function [Langer and Vacanti, 1993]. No matter the medical
application, the set of tools for the general concept of TE are identical; they include cells,
scaﬀolds and biological factors. The complexity of this bio-engineering approach increases as
each component underlies various inﬂuences and new questions arise constantly (Figure 2). The
results published in this multidisciplinary ﬁeld over the last years are promising and exciting for
future Regenerative Medicine.
Figure 1: Mouse, also known as Auriculosaurus,
with a human-shaped cartilage-engineered ear on
its back. Bovine chondrocytes were seeded on a
synthetic biodegradable polymer made of poly-
glycolic acid [Cao et al., 1997].
1.1.1 Background
Surely, the paucity of donor organs for transplantation is one causal explanation for the rapid rise
of TE over the last 20 years. Millions of people are waiting on transplantation lists worldwide;
unfortunately, the number of needed organs outruns the amount of available ones.
1
1 INTRODUCTION
Figure 2: The key components of TE today and the complexity arising with choosing the most suitable
and applicable cell-scaﬀold-biological factor combination.
To date, the gold standard in tissue transplantation is the autologous graft (tissue taken from
another side of the body of the same patient) ensuring the immune acceptance, but at the same
time facing the drawbacks of a possible lack of tissue, increased pain and the risk of infection
at the additional operation site. Allografts (tissue taken from a donor of the same species)
are secondary options, because the patients' immune response needs to be manipulated with
immunosuppressive drugs [Halloran, 2004]. The use of cadaver skin as temporary dressings of
large-scale wounds is a well established allograft in today's clinics [Ratner, 2012]. The shortage
of donor organs is well known, but still the quantity of donor organs decreases every year. For
instance, the number of organ donors in Germany dramatically decreased in 2013 by 16.3%
compared to 2012 [German Organ Transplantation Foundation, 2014]. Bearing this in mind,
it is inevitable to explore other possibilities in order to compensate this issue by increasing the
number of available grafts for tissue recovery, renewal and regeneration.
1.1.2 Challenges
There are considerable hurdles in TE and the translation of products from bench to bedside.
Among implant failure or the scale-up potential of novel technologies, the question of an optimal
cell source is hard to answer.
One of the feasible candidates are stem cells because of their high proliferative capacity
and self-renewal potential [Pittenger et al., 1999]. Even more promising than multipotent
adult stem cells are embryonic stem cells which is due to their pluripotency [Evans et al., 1981].
Since their isolation bears the destruction of the embryo, their usage underlies strict regulations.
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In Germany for instance, embryonic stem cell research is restricted by the embryo protection
law [Federal Ministry of Justice and Consumer Protection, 1990]. It permits only authorized
institutions to work with cell lines that have been generated before May 1st, 2007 [Federal
Ministry of Justice and Consumer Protection, 2002].
With these issues in mind, research made a tremendous breakthrough, shifting towards the
generation of pluripotent cell lines from diﬀerent sources. One example are induced pluripotent
stem cells (iPSC) derived from somatic cells through transfection with deﬁned pluripotency-
associated transcription factors [Yamanaka, 2008]. The idea of iPSC replacing embryo-derived
cells, thus sidestepping ethical controversies in the future is promising; however, their generation
is based on the usage of viral transfection techniques and the introduction of oncogenes [Liu,
2008]. Another very recent approach converted somatic cells into the pluripotent state through
stimulus-triggered acquisition of pluripotency (STAP) with a strong external stimulus such as
low pH [Obokata et al., 2014]. Although this method is time-eﬃcient and bypasses the problems
arising with the conversion of iPSC described before, the results are critically discussed regarding
their reproducibility [Williams et al., 2014].
In general, the safety issue of cell-based solutions is critical. Due to oncogenes, animal-
derived products and viral transfections, hazardous eﬀects cannot be ruled out completely.
Furthermore, the ex vivo proliferation and diﬀerentiation of cells cannot reproduce the in vivo
situation in detail, thus bearing the risk of unpredictable malformations or spontaneous muta-
tions of the cells in the patient.
Gradually, comments on the adequacy and suﬃciency of animal models for human diseases
are surfacing. The Federation of European Laboratory Animal Science Associations, a science-
based association, tightly observes and documents animal welfare and experimentation in about
20 European countries. The improvement of documentation through the use of systematic
reviews and the reﬁnement of in vivo models (e.g. molecular-based disease models) is strongly
suggested to avoid redundant and unnecessary experimental procedures [Pound, 2004; Seok
et al., 2013]. Researchers hope to maximize information drawn from animal research through
the (novel) guideline ARRIVE (Animals in Research: Reporting In Vivo Experiments) [Kilkenny
et al., 2010]. Thus, scientists are facing multiple challenges and ethical debates before tissue-
engineered products can be safely implemented into the clinical settings.
1.2 Biology of the Skin and Wound Healing
The integumentary system is formed by the skin and its accessory structures (hair, nails, glands),
protecting the body against the outside world. It covers a surface area of about 1.5-2 m2 in
adult humans and is composed of three interlaced parts: the epidermis, the dermis, and the
hypodermis (Figure 3). The epidermis is the most outer part, composed of keratinized stratiﬁed
squamous epithelium, followed by the dermis, a thicker, connective tissue-rich part (collagen
types I and III, elastic ﬁbers and glycosaminoglycans). The subjacent hypodermis consists of
adipose and loose connective tissue anchors the dermis to the underlying fasciae [Tortora and
Derrickson, 2010]. There are many possibilities to disturb the orderly complexity of this organ,
such as chronic diseases, trauma or burns. Especially in these cases, instant and mid- to long-
term treatment is needed to restore the skins' barrier function and accelerate wound healing
[MacNeil, 2007].
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Cutaneous wound repair is a complex and dynamic cell-matrix-cytokine interaction, divided
into three phases which all overlap in time: (i) inﬂammation, (ii) tissue regeneration (inclu-
ding re-epithelialization and granulation tissue formation) and (iii) tissue re-organization [Clark,
1993]. Figure 3 depicts the key players and signals involved in this intricate process.
Figure 3: Wound healing in the
skin after three days. The com-
plex interaction of growth factors,
cytokines and various cell types
needs to be extremely balanced
and well-regulated [Epstein et al.,
1999].
(i) Immediately after wounding, the void is ﬁlled with blood, aiding in re-establishing of
homeostasis through the formation of a ﬁbrin clot and providing a provisional matrix. The
platelets in the ﬁbrin clot release growth factors such as platelet-derived growth factor (PDGF),
epidermal growth factor (EGF) and transforming growth factor-β1 (TGF-β1) to direct and
activate macrophages and ﬁbroblasts (in)to the wound [Martin, 1997]. Alongside these cells
and attracted by chemotactic factors generated by the complement cascade, inﬂammatory
neutrophils arrive at the wound site [Epstein et al., 1999]. Neutrophils, identiﬁable by their gra-
nular and polymorphonuclear appearance, immediately begin attacking and destroying invading
pathogens [Hall, 2010]. After fulﬁlling their tasks, they become senescent and are phagocytozed
by tissue macrophages [Newman et al., 1982]. Furthermore, monocytes inﬁltrate the wound
bed, mature into tissue macrophages and synthesize numerous cytokines, e.g. PDGF, TGF-α,
TGF-β and vascular endothelial growth factor (VEGF). They promote cell proliferation [Eming
et al., 2007], stimulate granulation tissue formation [Epstein et al., 1999] and facilitate tissue
debridement [Clark, 1993]. Macrophages are the leading phagocytic cell type in wound repair
and play a crucial role in the outcome of the healing response. It has been reported that delayed
wound closure can be attributed to a reduced inﬁltration of macrophages [Eming et al., 2007].
(ii) In response to the growth factors, epithelial cells at the wound edges start to proli-
ferate, leading to re-epithelialization. At the same time, adjacent ﬁbroblasts synthesize collagen,
remodel the extracellular matrix (ECM) and secrete enzymes, such as plasminogen activators
and collagenases [Epstein et al., 1999]. Newly formed granulation tissue (consisting of macro-
phages, ﬁbroblasts and loose connective tissue) slowly replaces the provisional matrix as new
capillaries provide oxygen and nutrients [Clark, 1993]. Tissue-type plasminogen activator (tPA)
and urokinase-type plasminogen activator (uPA) both activate plasmin, the main ﬁbrinolytic
enzyme to dissolve the ﬁbrin network and ease the way for migratory cells [Martin, 1997].
4
1 INTRODUCTION
Angiogenesis, a substantial part of successful wound healing, is promoted by ECM remodeling,
the migration of endothelial cells into the wound bed, and the secretion of VEGF and ﬁbroblast
growth factor-2 (FGF-2) by epithelial cells and macrophages [Martin, 1997]. Other soluble
factors that have angiogenic potential are VEGF, TGF-β, angiogenin and hepatocyte growth
factor (HGF) [Bussolino et al., 1992; Tonnesen et al., 2000].
(iii) After the establishment of granulation tissue, several growth factors initiate the diﬀeren-
tiation of ﬁbroblasts into myoﬁbroblasts. Based on this, wound contraction is induced, which
is additionally guided by the higher stiﬀness of the ECM. Scar tissue starts to form through the
production and bundling of collagen ﬁbers [Hinz, 2007]. At the end, after physiological wound
healing, a cell-depleted, collagen-intense ﬁbrotic scar without epidermal appendages remains
[Gurtner et al., 2008].
To date, the exact mechanisms and signaling pathways involved the wound healing process
remain to be elucidated [Shaw and Martin, 2009]. Complications in wound healing can have
detrimental eﬀects on the daily life of patients as well as the economics of medical care today.
Chronic wounds usually result from a poor and disordered interplay of the healing response and
can generally be categorized as venous ulcers, pressure sores or diabetic ulcers [Mustoe et al.,
2006]. Burn wounds through excessive thermal, chemical, electrical or radiation incidents can
be graded based on the severity from ﬁrst to fourth degree burns. Most of the times, the
outcomes are hypertrophic scars which show an excessive amount of ECM, interfering with
vascularization and cell proliferation at the side of injury [Gurtner et al., 2008].
The goal of researchers are to manage these and other pathological healing conditions. So
far, science has come a long way in understanding parts of the mechanisms involved, but still
several hurdles remain to be overcome. Advances in molecular biology and wound healing are
crucial to further develop alternative treatments for patients in need.
1.3 Skin Substitutes
Essentially, the tasks of skin substitutes are restoring the barrier function and aiding in wound
healing [MacNeil, 2007]. In the 1970s, the culture of skin cells, such as keratinocytes or
ﬁbroblasts in two-dimensional (2D) structures started [Rheinwald and Green, 1975]. Their
incorporation into biomaterials such as collagen was relatively easy and feasible [Bell et al.,
1981]. The principle by Bell et al. can be viewed as the basis for many of today's TE constructs.
The approaches to treat skin injuries strongly depend on the structures damaged: epidermis,
dermis or hypodermis (full-thickness). Regardless of the discrepancy between academic and
commercial goals, the best examples of both are mentioned below.
At the beginning of the 1980s, Yannas and co-workers successfully treated full-thickness
burns in humans with a bi-layer approach. The ﬁbrillar dermis was a polymeric membrane
composed of porous autologous cell-seeded collagen-chondroitin-6-sulfate and the epidermal
layer was made of silicone [Yannas et al., 1982]. About ten years later, Boyce et al. closed large
full-thickness burn wounds with composite grafts made of collagen-glycosaminoglycan, seeded
with autologous dermal ﬁbroblasts and epidermal keratinocytes [Boyce et al., 1993]. By the end
of the 1990s, the ﬁrst U.S. Food and Drug Administration (FDA)-approved commercial skin
products were launched. Apligraf® (Graftskin), a bi-layered, living skin construct of allogenic
dermis and epidermis derived from neonatal foreskin and bovine-derived type I collagen was
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shown to fasten and enhance wound healing of hard-to-heal venous leg ulcers [Falanga and
Sabolinski, 1999]. Following this trend, living skin equivalents were introduced for diabetic
and venous ulcers (Dermagraft) by Advanced Tissue Sciences (now Smith & Nephew) and
for burn patients (OrCel) by Ortec [Lysaght and Hazlehurst, 2004]. Over the years, more
cell-biomaterial hybrids or acellular products, consisting e.g. of gelatin, collagen, poly(lactic-
co-glycolic acid) (PLGA) or polyethylene glycol (PEG) were produced [Ratner, 2012]. Today,
skin substitutes are still the only viable TE structures commercially available while the list for
oﬀ-the-shelf usage and in vitro testing continues to grow.
Promising results derived from (cross-linked) bovine collagen matrices with incorporated
growth factors such as EGF, TGF-β or PDGF, which were described for wound healing as well
as for soft and hard tissue repair [Ksander and Ogawa, 1990; Nimni, 1997]. The application
of other combinations, such as FGF-1-loaded ﬁbrin scaﬀolds [Pandit et al., 2000], EGF-loaded
microspheres in gelatin sponges [Ulubayram et al., 2001] and EGF-functionalized electrospun
silk mats [Schneider et al., 2009] all resulted in reduced wound size compared to controls. Until
now, the only FDA-approved substance for growth factor delivery is becaplermin (PDGF-BB)
which is topically applied to debrided full-thickness wounds in diabetic patients [Wieman et al.,
1998].
A few years ago, mesenchymal stem cells were found to be strongly involved in wound
healing based on their various biological and physico-chemical functions and molecules (Chap-
ter 1.4). Animal studies were conducted to evaluate MSC eﬃcacy through local or topical
delivery in models of full-thickness, incisional or excisional wounds [Jackson et al., 2012]. The
incorporation of MSC into three-dimensional (3D) scaﬀolds such as collagen or a nano-ﬁbrillar
matrices positively contributed to vascularization and faster wound closure [Jackson et al.,
2012]. Autologous MSC delivered topically in ﬁbrin spray showed a stimulatory eﬀect on wound
closure in human and murine cutaneous wounds [Falanga et al., 2007]. Currently, there are
two phase II clinical trials investigating the eﬀect of injected MSC on wound healing in diabetic
foot and burn conditions [U.S. National Institutes of Health, 2014a].
1.4 Mesenchymal Stem Cells
Human mesenchymal stem cells (MSC) are multipotent cells, which can be isolated from many
diﬀerent tissues. The term multipotent refers to the cells' ability to form multiple cell types
of one particular lineage, for instance all the cells of the hematopoietic lineage. Cells that
are pluripotent, for example. embryonic stem cells, are able to form all lineages except extra-
embryonic tissue such as trophoblastic cells. When a whole organism can be produced from
one cell only, the cell is deﬁned as totipotent; in mammals these are the zygotes and the ﬁrst
cleavage morulae (until the 8-cell stage) [Jaenisch and Young, 2008]. In the early 1990s, the
term mesenchymal stem cell was coined [Caplan, 1991].
To date, bone marrow is the main source of MSC [Barry and Murphy, 2004], although other
origins for the isolation of MSC(-like) cells emerge [Zvaiﬂer et al., 2000; Zuk, 2002; Bieback,
2004; Huang et al., 2009]. MSC from all sources are characterized based on the pioneering
works of Friedenstein and Pittenger [Friedenstein et al., 1968; Pittenger et al., 1999]. Pittenger
also deﬁned their two stem cell characteristics: (i) the diﬀerentiation potential into lineages of
mesenchymal tissues and (ii) the potential to replicate as undiﬀerentiated cells [Pittenger et al.,
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1999]. A few years later, stem cells were found in tissue niches, which are microenvironments
composed of many non-stem cells, ECM and various factors to ensure their stemness. The
niche is adapted to the type of stem cells and their needs; it is also organized and remodeled
by them [Fuchs et al., 2004].
The International Society of Cellular Therapy established minimal criteria for the charac-
terization of MSC in order to assure a consistent terminology in laboratories around the globe
[Horwitz et al., 2005; Dominici et al., 2006]. Accordingly, MSC must:◆ be plastic-adherent in tissue culture ﬂasks,
◆ express the surface antigens CD73, CD90, and CD105 (≥ 95% +),
◆ lack the surface antigens CD14 or CD11b, CD34, CD45, CD79α or CD19 and HLA class II
(≤ 2% +),
◆ show diﬀerentiation into osteoblasts, adipocytes, and chrondrocytes in vitro.
Beside their mesodermal lineage diﬀerentiation, MSC inherit a certain plasticity, as they were
shown to diﬀerentiate into cells of neuroectodermal and endodermal origin (Figure 4) [Petersen,
1999; Woodbury et al., 2000; Xu et al., 2004].
Figure 4: Plasticity of bone marrow-
derived MSC. MSC are able to self-
renew (curved arrow), diﬀerentiate
towards mesodermal lineage (linear
arrows) and transdiﬀerentiate into
ectodermal and endodermal lineages.
As transdiﬀerentiation in vivo is deba-
table, arrows are dashed. Adapted
from [Uccelli et al., 2008].
MSC own a speciﬁc set of features making them a valuable cell source in biomedical applica-
tions and stem cell therapies. The strategies of stem cell therapies involve administration
of autologous or allogenic stem cells with or without scaﬀolds and cytokines to the patient.
Although they are promising to overcome issues such as traumatic injury [Hannoush et al.,
2011], ischemic stroke [Lee et al., 2010a], type 1 diabetes mellitus [Chhabra and Brayman,
2013] or allograft rejection after renal transplantation [Reinders et al., 2013], the processes
involve ex vivo cell culture conditions and need to overcome numerous hurdles, e.g. sample
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collection, heterogeneity of MSC and the best delivery route [Nemeth, 2014]. As researchers
are constantly unraveling MSC biology and functions in more details, it is just a matter of time
until safe and eﬃcient stem cell therapies will be in reach.
MSC are of great interest, particularly due to their major advantages of secreting numerous
biologically active factors. They can be categorized according to their eﬀects [da Silva Meirelles
et al., 2009]:
◆ immunomodulatory, e.g. TGF-β, HGF
◆ anti-apoptotic, e.g. VEGF, HGF, bFGF
◆ angiogenic, e.g. bFGF, IL-6, VEGF,
HGF, ECM molecules
◆ anti-scarring, e.g. bFGF, HGF
◆ chemoattractive, e.g. CCL2, SDF-1
◆ supportive, e.g. angiopoietin-1, SDF-1,
SCF, LIF
Analyzing the individual roles of each cytokine, especially in vivo, is a complicated matter,
owing to their multiple eﬀects exerted on their surroundings. To date, the exact mechanisms
remain to be elucidated [Chamberlain et al., 2007; Caplan, 2010].
However, immunosuppressive properties of MSC on various immune cells in vitro are attes-
ted [Aggarwal, 2005]. In vivo studies emphasize the hampering of graft-versus-host disease
when MSC are administered [Le Blanc et al., 2004; Bonﬁeld et al., 2010]. This is in part due
to their extremely low level of the human leukocyte antigen (HLA) class II, making them well
tolerable after allogenic transplantation, even in HLA-incompatible individuals [Le Blanc et al.,
2003]. The anti-apoptotic and angiogenic activites of human adipose tissue MSC are described
for hypoxia and normoxia conditions in vitro as well as for a mouse hindlimb ischemia model
[Rehman, 2004]. Although diﬀerent in vivo studies describe MSC involvement regarding the pre-
vention of scarring, the exact mechanisms are not yet fully understood. With the large amount
of chemoattractants secreted by MSC, a number of cell types, such as neutrophils, monocytes,
or lymphocytes can be targeted [Rollins, 1997]. Their supportive eﬀects on hematopoiesis and
their recruitment capacities on neural progenitors are attested [da Silva Meirelles et al., 2009].
Due to these properties, MSC are a potent source for applications in bone, cartilage, or
soft tissue TE [Tuan et al., 2003] and stem cell-based approaches for other systems such
as blood vessels, nervous tissue or skeletal muscle [Bianco and Robey, 2001]. Numerous in
vivo studies investigating burn, acute or chronic wounds highlight the beneﬁts of MSC in
skin wound healing. When transplanted, MSC accelerate the formation of granulation tissue
formation, reduce scarring and increase vascularization [Shumakov et al., 2003; Mansilla et al.,
2005; Vojtassák et al., 2006]. Systemic injection of MSC leads to MSC engraftment at the
site of injury, but also into other tissues, e.g. lung, spleen and liver [Chamberlain et al., 2007].
Interestingly, local delivery of exogenous bone marrow-derived MSC to skin wounds increased
homing to the wound site by endogenous MSC [Shin and Peterson, 2013].
Despite the signiﬁcant steps and continuous advancements in stem cell-based therapies,
several challenges remain. Heterogeneity, cell fusion, and transdiﬀerentiation are amongst the
topics that need to be addressed in the future.
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1.5 Biomaterials
In 1987, the term biomaterial was coined: A biomaterial is a nonviable material used in a
medical device, intended to interact with biological systems [Williams, 1987]. The amount of
biomaterials tested for use in TE is innumerable. Depending on the application, researchers
investigate polymers, metals, ceramics, glasses, hydrogels and countless composites thereof. If
any kind of manipulation (e.g. chemical or physical) is considered, the range of potential mate-
rials increases tremendously. Even though the number is large, only a few materials overcome
the scientiﬁc hurdles of in vitro and in vivo testing as well as regulatory issues to translate
them into the clinics [Spector, 2014]. In principle, biomaterials must fulﬁll certain criteria to
be usable in the clinics. These include, but are not limited to [Metcalfe and Ferguson, 2007]:
◆ bio- and blood compatibility
◆ safety
◆ non-toxicity and non-antigenicity
◆ easy handling
◆ sterility
◆ timed and controlled release of bio-
logicals (if any)
◆ controlled degradation (if any)
◆ minimal inﬂammatory reactivity
◆ minimal pain and scarring
◆ facilitated angiogenesis
◆ cost-eﬀectiveness
◆ appropriate chemical, physical and
mechanical properties
1.5.1 Collagen
Among the group of naturally occurring bio-polymers, collagen is a very promising one. Over
the past decades, its use has been constantly increasing, partly because of its high abundance in
animals as a connective tissue protein, amounting to approximately 25% of total body protein
in vertebrates [Stenzel et al., 1974]. In addition, its degradability in biological environments
along with its easy chemical and physical modiﬁcations make collagen attractive and versatile.
To date, over 20 distinct collagen types are known, all sharing a typical triple helical structure
[Parenteau-Bareil et al., 2010]. They diﬀer in their length of (non-)helical sections as well as
their α-chain conformations [Stenzel et al., 1974]. Three of these chains form the molecular
subunit of collagen, called tropocollagen, which self-assembles into ﬁbrils (Figure 5). The
collagen ﬁbrils aggregate to form collagen ﬁbers [Friess, 1998]. The three most commonly
used types of ﬁbrillar collagen are type I, II, and III. Type I collagen constitutes skin, bone and
tendons, type II collagen commonly makes up cartilage, while type III collagen is predominantly
found in the vasculature [Ratner, 2012].
The sources of ﬁbrillar collagen in research are mostly bovine (bearing the risk of bovine
spongiform encephalopathy), porcine or murine; intriguingly, collagen can also be extracted
from the umbrellas of jellyﬁsh or alligators [Song et al., 2006; Wood et al., 2008].
Already in the 1970s, collagen with diﬀerent ﬁbrillar structures was used for implantation
studies and described as a potential drug and cell delivery system [White et al., 1973]. Based
on its structural support in vivo, its low immunogenicity and easy implantability a bright future
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Figure 5: Schematic structure of collagen
composition. Three α-chains constitute one
tropocollagen molecule with a length of about
300 nm and a diameter of about 1-2 nm.
A bundle of tropocollagen molecules self-
assembles into one microﬁbril with a length of
about 1 µm and a diameter of about 5 nm. The
ﬁbrils aggregate to form collagen ﬁbers with a
length of about 1 cm and a diameter of about
500 nm. Adapted from [Buehler, 2006; Shoul-
ders and Raines, 2009].
for collagen in bioengineering was predicted [Stenzel et al., 1974]. Numerous applications of
collagen-based biomaterials have been implemented over the years: blood vessels, soft tissue
augmentation, nerve regeneration and artiﬁcial skin are just a few examples [Ratner, 2012]. To
outweigh some of collagens' disadvantages (Table 1), combinations with other (bio)materials for
tissue regeneration were investigated; for instance collagen and glycosaminoglycans as wound
dressings, collagen and hydroxyapatite for bone repair [Chevallay and Herbage, 2000] and
collagen-silk ﬁbroin hybrids for the regeneration of skin or the central nervous system dura
mater [Ghezzi et al., 2011].
Table 1: Collagen as a biomaterial. Adapted from [Lee et al., 2001].
Advantages Disadvantages
Large availability High cost of pure type I collagen
Non-antigenicity High variability of isolated collagen
Biodegradability Variability in enzymatic degradation
Non-toxicity Hydrophilicity
Easy modiﬁcation Poor mechanical performance
Compatibility with other biomaterials Possible mineralization
1.5.2 Fibrin
Fibrin, another naturally derived biodegradable material, is majorly involved in blood clotting
and contributes strongly to the inﬂammatory response and wound healing [Mosesson, 2005]. It
is generated through proteolysis of ﬁbrinogen by thrombin [Ahmed et al., 2008]. Fibrinogen, a
plasma glycoprotein of about 340 kDa, is synthesized mainly by hepatocytes. Its structure is
composed of three pairs of polypeptide chains (AαBβγ)2 that are connected through 29 disulﬁde
bonds. Located in the middle region of the peptide are the ﬁbrinopeptides A and B, which are
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cleaved through thrombin, thus starting the conversion of ﬁbrinogen into ﬁbrin (Figure 6).
Thrombin is a serine protease that is produced from the cleavage of pro-thrombin by factor X
from the coagulation cascade. The sides of the cleaved ﬁbrinopeptides A and B interact in a
speciﬁc manner with the molecule to form protoﬁbrils [Janmey et al., 2009]. The 3D network is
formed through lateral aggregation of the ﬁbrin ﬁbers which essentially is the ﬁbrin clot [Weisel,
2005].
Figure 6: Schematic representation of the
formation of ﬁbrin. The cleavage of ﬁbrino-
peptides from ﬁbrinogen through thrombin
causes polymerization and formation of ﬁbrin
protoﬁbrils. These ﬁbrils aggregate three-
dimensionally to form ﬁbrin ﬁbers. Adapted
from [Chernysh et al., 2012].
Fibrin sources are essentially unlimited, as it is possible to purify ﬁbrin from blood plasma
of mammalian and non-mammalian sources. Especially for autologous purposes, ﬁbrin is a very
valuable biomaterial [Janmey et al., 2009].
Certainly, the natural role of ﬁbrin in hemostasis is utilized in clinical applications. The
FDA approved ﬁbrin as a sealant, drug delivery system, topical adhesive and hemostatic agent
[Spotnitz, 2010]. Even though its outstanding advantages contribute to ﬁbrins' high potential
medical applications such as urologic, vascular, intestinal, or neural medicine, its drawbacks
cannot be ignored (Table 2).
Table 2: Fibrin as a biomaterial. Adapted from [Ahmed et al., 2008].
Advantages Disadvantages
Natural occurrence No long term stability
High tissue-like water content Shrinkage potential
Autologous scaﬀold material Low mechanical stiﬀness
Good adhesion capability Rapid degradation
Over the years, merging of ﬁbrin (sealant) with other materials such as hydroxyapatite
granules to improve mechanical stiﬀness in bone TE or the production of ﬁbrin-polylactide-
based vascular grafts to overcome issues in graft availability in vascular TE [Le Guéhennec
et al., 2004; Koch et al., 2010] developed.
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1.5.3 Bombyx Mori Silk
The use of silk sutures dates back centuries [Mackenzie, 1973]. Silk is a naturally occurring,
ﬁbrous protein of non-mammalian origin. The silk ﬁber derives from the silk worm (Bombyx
mori) and is composed of two proteins: sericin and ﬁbroin. The hydrophilic sericin (20-310 kDa)
surrounds two ﬁbroin proteins which consist of one light (∼29 kDa) and one heavy (∼390 kDa)
chain, both connected with a disulﬁde bond [Vepari and Kaplan, 2007]. Sericin is a sticky, glue-
like protein, holding together the ﬁbroin chains which are orderly arranged into β-sheet crystal
regions and semi-crystalline regions based on hydrophobic domains in the primary structure
[Altman et al., 2003; Vepari and Kaplan, 2007]. Due to hypersensitivity and biocompatibility
issues, sericin is removed from ﬁbroin in a de-gumming procedure before silk is further processed
[Altman et al., 2003]. For this, silk cocoons are boiled in an alkaline solution, followed by
thorough washing with water for the extraction of sericin proteins [Jin et al., 2005]. The
de-gummed silk can then be manipulated into various forms such as ﬁbers, nano-particles,
membranes or 3D scaﬀolds. This is the most common approach in the production of sericin-
free silk.
The silk in this study underwent a diﬀerent manufacturing process. Spintec Engineering,
a company located in Aachen, is specialized on producing silk ﬁbroin-based products for
biomedical applications. They use genetically engineered silk worms to covalently link bio-
pharmaceuticals to silk ﬁbroin. In our case, HGF was covalently linked to silk ﬁbroin light
chains (Figure 7).
Figure 7: Covalent linkage of HGF to silk ﬁbroin. The growth factor (green dots) is linked to the light
chains (white dots) of the protein complex. HGF is expressed as a HGF/silk ﬁbroin light chain fusion
protein. Adapted from Spintec Engineering, Aachen.
The advantage of this silk ﬁbroin is the naturally sericin-free production, achieved through
direct isolation of the ﬁbroin-producing silk gland while discarding the sericin-producing gland
(Chapter 2.2.6.3). One outstanding advantage of silk is its high tensile strength which accounts
for its frequent use in ligament and cartilage TE [Altman et al., 2002; Meinel et al., 2004]. Other
properties of native silk ﬁbroin are highlighted in Table 3. As with all scaﬀold materials, silk
ﬁbroin can be conjoined with other materials such as collagen type I or hydroxyapatite to
enhance ligament regeneration or wound healing [Chen et al., 2008; Okabayashi et al., 2009].
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Table 3: Silk as a biomaterial. Adapted from [Altman et al., 2003; Meinel et al., 2005; Vepari and
Kaplan, 2007].
Advantages Disadvantages
Mechanical properties Biocompatibility issues with sericin
Surface and genetic modiﬁcations Slow degradability
Morphological ﬂexibility Variable degradation rates
Environmental stability Foreign body response
Sterilization possibilities Potential allergen
1.6 Hepatocyte Growth Factor and c-Met
Originally, HGF was identiﬁed in a rat study of liver regeneration which indicated HGF to be a
mitogen for rat hepatocytes [Nakamura et al., 1984]; its name is derived from this ﬁrst known
function of growth stimulation in hepatocytes [Nakamura, 1991]. Later, several groups puriﬁed
HGF from rat platelets, human plasma and rabbit plasma [Nakamura et al., 1987; Gohda et al.,
1988; Zarnegar and Michalopoulos, 1989]. Around the same time, scatter factor and tumor
cytotoxic factor were found to be identical to HGF [Bottaro et al., 1991; Shima et al., 1991].
The structure of this pleiotropic cytokine is composed of a 69 kDa α−chain and a 34 kDa
β−chain which are held together by a disulﬁde bond [Nakamura, 1991]. The α−chain includes
an N-terminal hairpin loop and four kringle domains, whilst the β−chain is homologous to
serine proteases, but without any proteolytic activity (Figure 8) [Organ and Tsao, 2011]. HGF
is secreted as a single chain, biologically inert precursor. Its conversion to its bioactive two-chain
form is mainly carried out through tissue or urokinase plasminogen activators (tPA and uPA,
respectively) [Mars et al., 1993].
The liver is able to regenerate itself after injury; its cells, mainly Ito and Kupﬀer cells,
produce high amounts of HGF [Michalopoulos and Zarnegav, 1992]. Over the years more and
more HGF-producing cell types were identiﬁed, such as endothelial cells, mast cells, MSC,
macrophages and apoptotic cells [Zarnegar and Michalopoulos, 1995; Neuss et al., 2004]. As
mentioned before (Chapter 1.2 and Chapter 1.4), HGF exerts a multitude of biological eﬀects
on its surroundings. Especially interesting for this study are its angiogenic potential [Bussolino
et al., 1992], its chemotactic potential on MSC [Neuss et al., 2004] and its strong involvement
in wound healing [Yoshida et al., 2003; Chmielowiec et al., 2007].
Its receptor was discovered as the c-met proto-oncogene product, a 190 kDa heterodimeric
transmembrane protein [Naldini et al., 1991]. Interestingly, c-Met is the only known receptor of
HGF. This fact is unusual given that a single growth factor usually has several similar ligands
[Nakamura et al., 2011]. C-Met belongs to the subfamily of heterodimeric receptor tyrosine
kinases and is the best-characterized one among them. It is composed of several structural
domains [Maulik et al., 2002]: sema, PSI and IPT are the domains constituting the extracellular
portion while the juxtamembrane domain and the tyrosine kinase domain are located intra-
cellularly. Additionally, the transmembrane domain functions as a connector between extra-
and intracellular space and a multifunctional docking site is attached to the kinase domain.
This cell surface receptor is expressed in epithelial cells of the liver, pancreas, prostate, kidney,
muscle and bone marrow in embryogenesis and also in adults [Comoglio et al., 2008].
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Figure 8: Left side: Schematic structure of HGF and its receptor c-Met. HGF consists of of an α-chain
and a β-chain linked by a disulphide bond. The heterodimeric structure of c-Met is composed of three
extracellular domains and two intracellular domains plus a multifunctional docking site. The intracellular
space is highlighted in orange. Right side: Upon binding of HGF to c-Met, the tyrosine kinase domain
and the docking site become phosphorylated, resulting in diverse cellular responses. Schematics adapted
from [Liu, 2004; Comoglio et al., 2008; Faria et al., 2011].
The HGF/c-Met pathway is followed by a large signaling complex (Figure 8). The binding
of HGF to c-Met results in phosphorylation of the tyrosines in the multifunctional docking site.
They recruit diﬀerent signaling eﬀectors, e.g. adaptor proteins (GRB2, SHC, Gab1), signal
transducers (PI3K, Stat3, SOS), the Src kinase and the SHP2 phosphatase [Maulik et al.,
2002]. Several other tyrosines can also contribute to c-Met signaling [Organ and Tsao, 2011].
Since the HGF/c-Met pathway is tightly controlled, any abnormal signaling or over-expression
may lead to tumorigenesis or metastasis [Faria et al., 2011].
Due to the multitudinous involvements of HGF/c-Met in epithelial morphogenesis, cell
motility, tissue repair, organ regeneration, but also cancer development and metastasis, its
potential for pharmaceutical therapies is studied. One group already reported safety and eﬃcacy
of HGF for the treatment of limb perfusion and wound healing of ischemic ulcers [Powell et al.,
2010]. Currently, one investigation is focused on the safety of adenovirus HGF for the treatment
of ischemic heart disease [U.S. National Institutes of Health, 2014b].
1.7 Study Design
The commonly utilized TE approach as mentioned in Chapter 1.1 entails several drawbacks.
For one, the patients' own cells or tissue is isolated, expanded and diﬀerentiated in vitro. The
cells are seeded on a biomaterial before transplanting the cell-biomaterial hybrid into the patient
(Figure 9). Usually, this approach is time-intensive, costly and often entails increased pain for
the patient as well as a higher risk of infection and inﬂammation.
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Therefore, our project aims to circumvent these issues by directly implanting an HGF-loaded
biomaterial for the in vivo recruitment of endogenous MSC. HGF is beneﬁcial for wound healing
in vivo because it leads to increased granulation tissue formation, neo-angiogenesis and faster
re-epithelialization [Werner and Grose, 2003; Yoshida et al., 2003; Bevan et al., 2004]. Since
MSC are involved in wound healing and thought to emigrate out of their niches to the wound
side, they also could enhance wound healing and aid in re-establishing tissue function. In
our model, HGF release should be controlled and gradual over time to stimulate the directed
migration of MSC. The behavior of MSC migration towards an enhanced HGF concentration
in vitro was already described by Neuss and co-workers [Neuss et al., 2004]. The advantages
of this approach are the time- and cost-eﬃciencies as well as the pain-reduced solution for the
patient through immediate implantation of the HGF-loaded biomaterial onto the defect region.
Ultimately, our project is viewed as a possible application for patients with chronic ulcers or
burn victims in need of an instantaneous solution.
Figure 9: Novel (left side) and general (right side) approach in TE. We aim to develop HGF-loaded
(blue circles) biomaterials that can be directly implanted in order to recruit endogenous MSC out of their
niches and into the wound site. This way, the costly and longsome multi-step procedures of ex vivo cell
isolation, expansion and diﬀerentiation can be circumvented. In addition, the biomaterials are available
oﬀ-the-shelf and can therefore be utilized as wound dressings for patients in need of prompt coverage,
such as burn victims, but also for patients suﬀering from chronic ulcers or hard-to-heal wounds.
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1.8 Goals
This thesis was aimed at developing a novel system to recruit endogenous MSC out of their
niches and to the site of injury to improve wound healing in vivo. Three natural biomaterials,
collagen, ﬁbrin and transgenic silk worm-derived silk ﬁbroin were analyzed regarding MSC mi-
gration and recruitment in vitro and in vivo. HGF was incorporated into all three biomaterials
and directed MSC migration behavior was elucidated This thesis is divided into three parts:
1. HGF-incorporation into collagen gels, ﬁbrin gels and silk ﬁbroin membranes and its release
in vitro
◆ Can HGF be incorporated into collagen gels, ﬁbrin gels and silk ﬁbroin?◆ How are the HGF release kinetics from collagen, ﬁbrin and silk ﬁbroin in vitro?
2. MSC mobilization in vitro
◆ Do HGF-loaded biomaterials aﬀect MSC migration in vitro?◆ Is the HGF-receptor c-Met essential for MSC migration in vitro?
3. In vivo responses towards HGF-loaded and HGF-free implants
◆ Are the biomaterials tolerated in vivo and how stable are they?◆ What are the short and long term immune responses against HGF-free and HGF-
loaded biomaterials? (Master's Thesis by Vera Paefgen, December 2013)◆ Do HGF-loaded biomaterials elicit endogenous MSC migration in the mouse?
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2 Materials and Methods
2.1 Materials
2.1.1 Consumables
Capsules Medite, Burgdorf, DE
Cell Culture Inserts Ibidi, Martinsried, DE
Cell Crowns

Sigma-Aldrich, Steinheim, DE
Cryovials 1.8 ml Nunc, Roskilde, DK
Dialysis Membrane Roth, Karlsruhe, DE
Eppendorf Tubes 1.5 ml & 2 ml Eppendorf, Cologne, DE
Erlenmeyer & Laboratory Flasks Schott, Mainz, DE
FACS Tubes Becton Dickinson, Heidelberg, DE
Falcon Tubes 15 ml & 50 ml Falcon, Heidelberg, DE
Funnel & Reservoir Bottles Millipore, Schwalbach, DE
Lint-Free Cloth Wepa, Arnsberg, DE
Measuring Cylinders Brand, Wertheim, DE
Microscope Slides Dako, Hamburg, DE
Nitrile Gloves Sempermed, Gevelsberg, DE
Pasteur Pipettes Brand, Wertheim, DE
PCR Plates Applied Biosystems, Darmstadt, DE
Pipettes 5 ml, 10 ml, 25 ml Falcon, Heidelberg, DE
Pipette Tips 10 µl, 200 µl, 1000 µl Sarstedt, Nuembrecht, DE
Sterile Filter 0.22 µm Millipore, Schwalbach, DE
Sterile Filter, Bell-Shaped Sartorius, Goettingen, DE
Syringes 1 ml, 2 ml, 5 ml, 50 ml Braun, Melsungen, DE
Tissue Culture & Multiwell Plates Greiner, Frickenhausen, DE
Transwells
®
Corning Costar, Corning, US
2.1.2 Chemicals and Solvents
Acetic Acid (C2H4O2) Merck, Darmstadt, DE
Acetone (C3H6O) Sigma-Aldrich, Steinheim, DE
Acid Fuchsin Waldeck, Muenster, DE
Agarose Sigma-Aldrich, Steinheim, DE
Alizarin Red Powder Sigma-Aldrich, Steinheim, DE
Ammonium Hydroxide (NH4OH) Sigma-Aldrich, Steinheim, DE
Aqua ad injectabilia Braun, Melsungen, DE
β−Mercaptoethanol Invitrogen, Darmstadt, DE
Calcium Chloride (CaCl2) Roche, Mannheim, DE
Citrate Buﬀer Merck, Darmstadt, DE
Citric Acid (C6H8O7) Merck, Darmstadt, DE
Collagen I/III Biochrom, Berlin, DE
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DAPI I (1000 ng/ml) Abbot, Wiesbaden, DE
DEPC-Water Sigma-Aldrich, Steinheim, DE
Dimethyl Sulfoxide ((CH3)2SO) Merck, Darmstadt, DE
DNAse I from Bovine Pancreas Sigma-Aldrich, Steinheim, DE
Eosin Y Sigma-Aldrich, Steinheim, DE
Ethanol (C2H6O) Sigma-Aldrich, Steinheim, DE
Ethidium Bromide (C21H2OBrN3) Allichem, Baltimore, US
Formaldehyde Solution Fischar, Saarbruecken, DE
GBSH5 Buﬀer Homemade, see Chapter 2.1.3.7
Glutaraldehyde (CH2(CH2CHO)2) Agar Scientiﬁc, Wetzlar, DE
HGF PromoCell, Heidelberg, DE
Hemacolor
®
Merck, Darmstadt, DE
Hemalaun Sigma-Aldrich, Steinheim, DE
Human Fibrinogen Sigma-Aldrich, Steinheim, DE
Hydrogen Chloride (HCl) Merck, Darmstadt, DE
Immu-Mount

Fisher Scientiﬁc, Schwerte, DE
Isoﬂurane (C3H2ClF5O) Baxter, Deerﬁeld, US
Isopropanol ((CH3)2CHOH) Sigma-Aldrich, Steinheim, DE
Matrigel

Basement Membrane Becton Dickinson, Heidelberg, DE
Mayer's Hematoxylin Merck, Darmstadt, DE
Methanol (CH3OH) VWR, Darmstadt, DE
NP-40 Sigma-Aldrich, Steinheim, DE
Oil Red O Powder Sigma-Aldrich, Steinheim, DE
Paraﬃn Leica, Wetzlar, DE
Paraformaldehyde (OH(CH2On)H) Fischar, Saarbruecken, DE
PBS Invitrogen, Darmstadt, DE
Picric Acid (C6H3N3O7) Pharmacy, University Hospital Aachen, DE
Periodic Acid Solution Merck, Darmstadt, DE
Sodium Citrate Merck, Darmstadt, DE
Sodium Hydroxide (NaOH) Sigma-Aldrich, Steinheim, DE
TGF-β3 R&D Systems, Wiesbaden, DE
Thrombin Sigma-Aldrich, Steinheim, DE
Tissue Plasminogen Activator (tPA) American Diagnostica, Pfungstadt, DE
Toluidine Blue Powder Sigma-Aldrich, Steinheim, DE
Tris/Borate/EDTA Buﬀer, pH 9.0 Dako, Hamburg, DE
Trypsin Invitrogen, Darmstadt, DE
Vitro-Clud
®
Langenbrinck, Emmendingen, DE
Xylene (C8H10) VWR, Darmstadt, DE
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2.1.3 Cell Culture Media, Supplements and Reagents
2.1.3.1 Human Mesenchymal Stem Cell Medium
Human Stem Cell Medium PAN Biotech, Aidenbach, DE
+ 100 U/ml Penicillin PAA, Coelbe, DE
+ 100 µg/ml Streptomycin PAA, Coelbe, DE
+ 2 mM L-Glutamine PAA, Coelbe, DE
+ 2% FCS PAN Biotech, Aidenbach, DE
2.1.3.2 Osteogenic Diﬀerentiation Medium
DMEM 1.0 g/l Glucose PAA, Coelbe, DE
+ 100 U/ml Penicillin PAA, Coelbe, DE
+ 100 µg/ml Streptomycin PAA, Coelbe, DE
+ 2 mM L-Glutamine PAA, Coelbe, DE
+ 100 nM Dexamethasone Sigma-Aldrich, Steinheim, DE
+ 10 mM β-Glycerophosphat Sigma-Aldrich, Steinheim, DE
+ 0.05 mM L-Ascorbic Acid Sigma-Aldrich, Steinheim, DE
+ 10% FCS PAN Biotech, Aidenbach, DE
2.1.3.3 Adipogenic Maintenance Medium
DMEM 4.5 g/l Glucose PAA Laboratories, Freiburg, DE
+ 0.01 mg/ml Insulin Sigma-Aldrich, Steinheim, DE
+ 100 U/ml Penicillin PAA, Coelbe, DE
+ 100 µg/ml Streptomycin PAA, Coelbe, DE
+ 2 mM L-Glutamine PAA, Coelbe, DE
+ 10% FCS PAN Biotech, Aidenbach, DE
2.1.3.4 Adipogenic Induction Medium
Adipogenic Maintenance Medium See 2.1.3.3
+ 0.2 µM Indomethacin Biomol, Hamburg, DE
+ 1 µM Dexamethasone Sigma-Aldrich, Steinheim, DE
+ 0.5 mM IBMX Sigma-Aldrich, Steinheim, DE
2.1.3.5 Chondrogenic Diﬀerentiation Medium
DMEM 4.5 g/l Glucose PAA Laboratories, Freiburg, DE
+ 100 nM Dexamethasone Sigma-Aldrich, Steinheim, DE
+ 0.17 mM L-Ascorbic Acid- Sigma-Aldrich, Steinheim, DE
2-Phosphate
+ 100 µg/ml Sodium Pyruvate Sigma-Aldrich, Steinheim, DE
+ 40 µg/ml Proline Sigma-Aldrich, Steinheim, DE
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+ 5 ml ITS-Plus Sigma-Aldrich, Steinheim, DE
+ 100 U/ml Penicillin PAA, Coelbe, DE
+ 100 µg/ml Streptomycin PAA, Coelbe, DE
+ 2 mM L-Glutamine PAA, Coelbe, DE
+ 10 ng/ml TGF-β3 (fresh) R&D Systems, Wiesbaden, DE
2.1.3.6 Murine Stem Cell Medium
DMEM 4.5 g/l Glucose PAA Laboratories, Freiburg, DE
+ 1% L-Glutamine, PAA, Coelbe, DE
Penicillin, Streptomycin
+ 10% FCS PAN Biotech, Aidenbach, DE
2.1.3.7 GBSH5 Buﬀer
Aqua bidest. Braun, Melsungen, DE
+ 1.5 nM CaCl2 x 2H2O Roche, Mannheim, DE
+ 0.2 mM KH2PO4 Merck, Darmstadt, DE
+ 121.0 mM NaCl Merck, Darmstadt, DE
+ 4.5 mM KCl AppliChem, Darmstadt, DE
+ 1.0 mM MgCl2 x 6H2O AppliChem, Darmstadt, DE
+ 0.6 mM MgSO4 x 7H2O Sigma-Aldrich, Steinheim, DE
+ 0.8 mM Na2HPO4 Roth, Karlsruhe, DE
+ 5.0 mM HEPES Millipore, Schwalbach, DE
2.1.4 Primer
Table 4: Primer, manufactured by Euroﬁns MWG, Ebersberg, DE
Primer Nucleotide Sequence Product Length in bp
β-actin Fw 5'-TGG CAC CAC ACC TTC TAC AAT GAG C-3' 51
Rv 5'-GCA CAG CTT CTC CTT AAT GTC ACG C-3'
c-Met Fw 5'-AGA AAT TCA TCA GGC TGT GAA GCG CG-3' 441
Rv 5'-TTC CTC CGA TCG CAC ACA TTT GTC G-3'
2.1.5 Kits
Cell Titer-Blue
®
Cell Viability Promega, Mannheim, DE
Dako REAL

Detection System, Dako, Hamburg, DE
Peroxidase/DAB+, Rabbit/Mouse
Go Taq
®
Flexi DNA Polymerase Promega, Mannheim, DE
Kit (500 U)
High Capacity cDNA Synthesis Kit Applied Biosystems, Darmstadt, DE
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RNeasy
®
Mini Kit Qiagen, Hilden, DE
Transfection Kit c-Met Qiagen, Hilden, DE
HGF ELISA Kit PromoCell, Heidelberg, DE
XTT Proliferation Kit Roche, Mannheim, DE
2.1.6 Antibodies
Table 5: Primary and secondary antibodies for ﬂow cytometry, immunohistochemistry and
immunoﬂuorescence.
Antibodies for ﬂow cytometry
CD34-FITC, 1:100, monoclonal mouse anti-human Miltenyi Biotec, Bergisch-Gladbach, DE
CD45-APC, CD73-APC, CD90-FITC, CD105-PE, Becton Dickinson, Heidelberg, DE
1:100, monoclonal mouse anti-human
Isotype Controls (APC-/FITC-/PE-Mouse IgG1κ), Becton Dickinson, Heidelberg, DE
1:100, mouse monoclonal antibody
Antibodies for immunohistochemistry
CD20 & CD117, 1:800, polyclonal rabbit anti-mouse Antibodies-online, Aachen, DE
CD68, 1:500, monoclonal rat anti-mouse AbD Serotec, Dusseldorf, DE
Immunoglobulins/biotinylated polyclonal goat Dako, Hamburg, DE
anti-mouse & anti-rabbit
Antibodies for immunoﬂuorescence
C-Met, 1:50, polyclonal rabbit anti-mouse Santa Cruz, Heidelberg, DE
Blocking peptide anti c-Met Santa Cruz, Heidelberg, DE
Immunoglobulins/biotinylated 1:250, polyclonal goat Dako, Hamburg, DE
anti-rabbit
Streptavidin-FITC 1:250 Dako, Hamburg, DE
Nucleostemin, 1:50, polyclonal goat anti-mouse R&D Systems, Wiesbaden, DE
Northern Lights 557, 1:200, donkey anti-goat R&D Systems, Wiesbaden, DE
2.1.7 Equipment
7300 Real Time PCR System Applied Biosystems, Darmstadt, DE
Autoclave 2540 EL Tuttnauer, Breda, NL
Autostainer DAKO Cytomation Dako, Hamburg, DE
Biofuge Pico, Rotor # 3325 Heraeus, Duesseldorf, DE
& Primo R, Rotor # 75007588
CASY
®
Roche, Mannheim, DE
Dako Autostainer Plus Dakocytomation, Hamburg, DE
Embedding Unit Fisher Scientiﬁc, Schwerte, DE
FACSCanto

II Becton Dickinson, Heidelberg, DE
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Fluorometer FLUOstar OPTIMA BMG Labtech, Jena, DE
Fridge & Freezer Combination Bosch, Munich, DE
Gel Electrophoresis Chamber Serva, Heidelberg, DE
& Power Supply
Hot Cabinet Heraeus, Duesseldorf, DE
Incubator (20% O2, 5% CO2, 37
○C) Thermo Scientiﬁc, Bonn, DE
Lamina Flow Cabinet Heraeus, Duesseldorf, DE
Magnetic Stirrer with Heating IKA, Staufen, DE
Microscope Leica DM IL Leica, Wetzlar, DE
Microscope Slide Scanner Hamamatsu Photonics,
NanoZoomer 2.0 HT Hamamatsu City, JP
Microtome Leica RM2145 Leica, Wetzlar, DE
Microwave Sharp, Mahwah, US
Multifuge 3L, Rotor # 75006445 Heraeus, Duesseldorf, DE
NanoDrop 1000 Fisher Scientiﬁc, Schwerte, DE
Nikon D5-100 Camera Nikon, Duesseldorf, DE
Pipette Boy Accu-jet
®
Brand, Wertheim, DE
Oak Ridge Centrifuge Tube Fisher Scientiﬁc, Schwerte, DE
Scale Sartorius Analytic Sartorius, Goettingen, DE
Tecan Inﬁnite M200
®
Tecan, Carlsheim, DE
Thermal Cycler, C1000

Bio Rad, Munich, DE
Thermomixers 5436 & Compact Eppendorf, Cologne, DE
VacuSafe Comfort INTEGRA Biosciences, Zizers, CH
2.1.8 Animals and Materials for in vivo Experiments
C57BL/6 Mice Charles River, Sulzfeld, DE
Carprofen Pﬁzer, Berlin, DE
Depilatory Lotion Reckitt Benckiser, Mannheim, DE
Dexpanthenol Bayer, Leverkusen, DE
Heated Plate Medax, Neumuenster, DE
Injection Needles Braun, Melsungen, DE
Isoﬂuorane AbbVie, Wiesbaden, DE
Ketamine, 10% Ceva, Duesseldorf, DE
Povidone-Iodine Solution Mundi pharma, Limburg, DE
Scalpels Pfm medical, Cologne, DE
Shaver BaByliss, Hampshire, UK
Surgical Masks 3M Health Care, Neuss, DE
Surgical Tweezers & Scissors Roth, Karlsruhe, DE
Reﬂex Wound Clip System Fine Science Tools, Heidelberg, DE
& 9 mm Wound Clips
Xylazine, 2% Bernburg AG, Aschberg, DE
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2.1.9 Software
Adobe Photoshop 8.0 Adobe, Munich, DE
AnalySIS pro 5.0 Olympus Soft Imaging Solutions,
Muenster, DE
Diskus 4.80.4313 Hilgers, Koenigswinter, DE
FACSDiva Software V7.0 Becton Dickinson, Heidelberg, DE
FlowJo 5.7.2 Tree Star, Ashland, US
GraphPad Prism

6.0 GraphPad Software, La Jolla, US
Leica Application Suite 2.2.1 Leica, Wetzlar, DE
NanoDrop 1000, 3.7.0 Fisher Scientiﬁc, Schwerte, DE
NDP.view 2 Hamamatsu Photonics, Hamamatsu City, JP
Octave 3.4.2 Freeware
OpenOﬃce 3.2.1 Freeware
TeXnicCenter 2.0 Beta Freeware
2.2 Methods
All cell culture methods were carried out under sterile conditions (laminar ﬂow cabinet) and all
cells were incubated in a 20% O2 and 5% CO2 humidiﬁed atmosphere at 37
○C.
2.2.1 Culture of Human Mesenchymal Stem Cells
Procedures were approved by the local ethics committee and human donors gave informed
consent. Human mesenchymal stem cells (MSC) were isolated from femoral heads according to
the protocols of Haynesworth et al. and Pittenger et al. [Haynesworth et al., 1992; Pittenger
et al., 1999]. MSC were maintained in human stem cell medium (SCM, Chapter 2.1.3.1) which
was changed every 3-4 days. Cell numbers were measured regularly with an electronic cell
counter. At 80-90% conﬂuence, stem cells were trypsinized with stem cell trypsin, transferred
into 50 ml falcons and centrifuged at 500 g for seven minutes (min). Then, MSC were reseeded
in a density of 5.000 cells/cm2 for optimal proliferation. If not needed, MSC were frozen in
medium with dimethyl sulfoxide (DMSO) in a ratio of 10:1. Cells in passages between two
and ﬁve were used for all experiments. MSC proliferation was measured with an XTT test,
a colorimetric assay which is roughly proportional to cell proliferation. For this, 0.16 x 105
cells/well were seeded in a 96-well plate. The supernatant was taken at diﬀerent time points
(1, 3, 7 and 14 days after seeding) and its absorption was measured photometrically at a
wavelength of 492 nm. Growth curves were plotted and doubling times TD were calculated
which were based on the absorption values with the equation
TD = ln2
µ
. (1)
All cells were characterized in vitro by multipotency and ﬂow cytometry (Chapter 2.2.2)
according to the standard protocols as required by the International Society for Cellular Therapy
[Horwitz et al., 2005; Dominici et al., 2006]. Three to ﬁve diﬀerent donors were used for the
characterization of MSC and all MSC-related experiments.
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2.2.2 Characterization of Human Mesenchymal Stem Cells
MSC were always seeded in SCM and diﬀerentiation media (Chapter 2.1.3) were added the
next day. MSC were cultured for each diﬀerentiation approach for 7, 14 and 21 days.
2.2.2.1 Morphology MSC morphology was checked the day after seeding and every time
the medium was changed. Cells were visualized under the microscope and pictures were taken
at diﬀerent magniﬁcations.
2.2.2.2 Surface Marker Expression To analyze cell surface marker expression, MSC were
trypsinized and counted as described before (Chapter 2.2.1). MSC were resuspended in phos-
phate buﬀered saline (PBS) and incubated with a directly labeled antibody (1:100) on ice for
30 min. Afterwards, MSC were washed and resuspended in PBS, transferred to FACS tubes and
ﬂuorescent intensities (at least 10.000 events) were measured. Unlabeled MSC served as a con-
trol and isotype controls were included to conﬁrm the level of speciﬁcity and for compensation
settings.
2.2.2.3 Osteogenic Diﬀerentiation MSC were seeded in a density of 31.000 cells/cm2 and
the medium was changed three times per week. For evaluation of diﬀerentiation, Alizarin Red
staining which marks the presence of calcium depositions produced by osteoblasts was carried
out [Gregory et al., 2004]. Medium was removed and cells were ﬁxed in 4% formaldehyde at
room temperature (RT) for 15 min. After two washing steps in aqua dest., incubation with
40 mM Alizarin Red (40 mM Alizarin Red powder in aqua dest., pH 4.1) followed on the rocker
for 30 min. MSC were visualized under the microscope after washing four times in aqua dest.
For quantiﬁcation of osteogenic diﬀerentiation, aqua dest. was removed and 10% acetic acid
was added for 30 min. Acid/MSC solution was transferred into 1.5 ml Eppendorf tubes and
heated at 85 ○C for ten min. Acid/MSC solution was cooled down on ice for ﬁve min, followed
by centrifugation at 16.000 g for 15 min. Afterwards, 200 µl of supernatant was mixed with
10% ammonium hydroxide and pipetted into a 96-well plate for absorption measurement at
405 nm. Undiﬀerentiated MSC served as a negative control.
2.2.2.4 Adipogenic Diﬀerentiation MSC were seeded in a density of 80.000 cells/cm2.
Adipogenic induction medium replaced SCM the next day. Induction and maintenance media
were alternated every three to four days. Diﬀerentiation was evaluated with Oil Red O staining,
marking lipid vacuoles produced by adipocytes. MSC were ﬁxed in 50% ice cold ethanol for
30 min and subsequently placed on rocker in Oil Red O staining solution (35 ml 0.2% (w/v)
Oil Red O powder in 100% methanol and 10 ml 1 M NaOH) for ten min. Staining solution was
replaced by tap water and MSC were visualized under the microscope.
2.2.2.5 Chondrogenic Diﬀerentiation MSC were seeded in a density of 250.000 cells/
0.5 ml in 15 ml falcons. Falcons were centrifuged at 500 g for seven min to establish a cell
pellet, the lid was cranked and falcons were placed in the incubator. Medium was changed three
times per week and transforming growth factor (TGF)-β3 was added freshly each time. Pellets
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were ﬁxed in 4% formaldehyde, embedded in agarose and dehydrated in an ascending ethanol
series over night. The next day, pellets were embedded in paraﬃn, cut at 3 µm thickness and
stained with Toluidine Blue (2 g Toluidine Blue powder in 200 ml acetate buﬀer, pH 4.66).
Proteoglycans in the extracellular matrix of chondrocytes appeared in blue or purple color.
2.2.3 Isolation and Culture of Murine Stem Cells
Murine stem cells were isolated from the femura and tibiae of C57BL/6 mice. These MSC were
used as control cells for immunoﬂuorescence of c-Met and nucleostemin. Mice were sacriﬁced
by inhalation of isoﬂuorane before cervical dislocation. Femura and tibiae were dissected,
sprayed with 70% ethanol and ﬂushed with 5 ml murine stem cell medium (Chapter 2.1.3.6).
Cell suspension was transferred into 50 ml falcons and centrifuged at 500 g for seven min.
Afterwards, cells were seeded in 10 cm cell culture dishes. The next day, cells were washed
with PBS and medium change occurred every two days. MSC were kept in culture until used
for ﬂuorescence staining.
2.2.4 C-Met siRNA Transfection of Mesenchymal Stem Cells
C-Met expression can be down-regulated by RNA interference which was carried out by c-Met
siRNA transfection. Human MSC were seeded in MSC medium in 6- or 24-well plates. The next
day, cells were transfected with c-Met siRNA. For this, medium was changed and transfection
agent was added in drops. The kit contained a transfection negative (without complementary
sequences) and a positive (apoptotic) control. Additionally, non-transfected MSC served as
control cells. MSC morphology was documented photographically after 24, 48 and 72 hours
(h) of transfection. After 72 h, medium was removed; cells were washed with PBS, trypsinized
with stem cell trypsin and cell suspension was transferred into Eppendorf tubes. Tubes were
centrifuged at 137 g for ﬁve min. Cell pellets were stored at -80 ○C for RNA isolation; afterwards
polymerase chain reaction and gel electrophoresis were carried out (Chapter 2.2.5). Transfection
was carried out for three donors.
2.2.5 Polymerase Chain Reaction and Gel Electrophoresis
Total RNA was isolated from human MSC with an RNeasy
®
Mini Kit according to the manu-
facturers' instructions. RNA content was measured photometrically, followed by a digestion step
with DNase I and 1 µg of RNA was reverse transcribed using a high capacity cDNA Synthesis
Kit. The cDNA was stored at -20 ○C until further use.
Polymerase chain reaction (PCR) was carried out with GoTaq
®
Flexi DNA Polymerase Kit
(500 U) for β-actin as housekeeping gene and c-Met (sequences in Table 4). PCR ampliﬁes spe-
ciﬁc regions of DNA during the processes of denaturation, annealing and elongation/extension.
For successful PCR, products in the range of 400 base pairs (bp) for β-actin and 440 bp for
c-Met were expected. Gel electrophoresis was carried out in a gel composed of 2% agarose with
ethidium bromide in tris base/borate acid/EDTA buﬀer at 130 Volt for 25 min. PCR and gel
electrophoresis were carried out for non-transfected and c-Met siRNA transfected MSC from
the same donors.
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2.2.6 Biomaterial Preparation
2.2.6.1 Collagen Gel Preparation Collagen gels were generated as previously described
[Schneider et al., 2010]. In brief, eight volumes of acidic collagen G (3 mg/ml collagen I/III
in 12 mM HCl) were mixed with one volume 10% 10-fold DMEM high-glucose, followed by
neutralization with 1 M NaOH. One volume of medium±HGF (75 ng/ml) was added to the
gel mixture. The gel was placed in bottom compartments of 24-well plates, incubated at 37 ○C
for 2 h to polymerize and medium was added afterwards. All results were obtained from ﬁve
independent experiments.
2.2.6.2 Fibrin Gel Preparation Fibrin gels were prepared by polymerization using 20 µl
thrombin (1000 U/ml) and 180 µl ﬁbrinogen in 24-well plates as described before [Neuss et al.,
2009a]. A ﬁbrinogen solution consisted of 830 µl human ﬁbrinogen solution (20 mg/ml), 50 mM
CaCl2, and 20 µl GBSH5 buﬀer without glucose and Ca
2+ (Chapter 2.1.3.7). Fibrinogen solution
was produced by dissolving 160 mg human ﬁbrinogen powder in 8 ml of aqua ad injectabilia and
eight ml of GBSH5 buﬀer without glucose and Ca
2+. The mixture was transferred into dialysis
membranes and equilibrated with GBSH5 buﬀer without glucose and Ca
2+ at 4 ○C over night.
The next day, ﬁbrinogen solution was placed in Oak Ridge Centrifuge Tubes and centrifuged at
1200 g for 30 min. The clear supernatant was aspirated, sterile ﬁltrated and frozen at -80 ○C.
Seventy-ﬁve ng/ml HGF were added before polymerization. The plate was shaken carefully to
enhance polymerization and incubated at 37 ○C for 20 min. After polymerization, medium was
added. All results were based on ﬁve independent experiments. For in vivo experiments, ﬁbrin
was stored at -20 ○C until use (approx. four hours) to prevent early HGF release.
2.2.6.3 Silk Fibroin Preparation Silk ﬁbroin implants from the silkworm Bombyx mori
were provided by Spintec Engineering. HGF-presenting silk ﬁbroin was produced by genetic
engineering of silkworms which expressed a fusion protein of ﬁbroin light chain and human
HGF in the silk gland. An additional batch expressed a fusion protein of ﬁbroin light chain
and tissue-type plasminogen activator (tPA) cleavage site and HGF to enable active release
of HGF. Through de-captivation, silk ﬁbroin could be directly isolated from the ﬁbroin gland
without contacting the glue-like sericin gland; therefore sericin-free silk was produced. HGF was
covalently linked to the silk ﬁbroin. The scaﬀold diameter and thickness were approx. 6 mm
and 0.4 mm, respectively. Three diﬀerent types of silk ﬁbroin were used for the experiments:
silk ﬁbroin, silk ﬁbroin with HGF and silk ﬁbroin with tPA cleavage site and HGF (only for in
vivo experiments).
2.2.7 HGF ELISA
An enzyme-linked immunosorbent assay (ELISA) is a quantitative test to measure the concen-
tration of a molecule. In principle, a speciﬁc antibody (here c-Met) was immobilized on the
bottom of the wells of a 96-well plate. Samples or quantiﬁcation standards were added to each
well which attached to the antibody. After washing, a second antibody was added which bound
to a diﬀerent site of the molecule. Following washing, an enzyme-coupled antibody was added
which coupled to the second antibody. At last, a substrate solution induced a color change
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and a stop solution ended the assay. The intensity of the color was measured as absorption
photometrically at 450 nm. The absorption was proportional to the amount of the bound
molecule. The concentration was calculated with the help of the standard which was included
in the kit. The HGF ELISA was carried out with a human HGF ELISA kit according to the
manufacturers' protocol (PromoCell). Collagen gels+HGF and ﬁbrin gels+HGF were produced
as described above (Chapter 2.2.6) and placed in 96-well plates. Silk ﬁbroin+HGF and silk ﬁ-
broin+tPA cleavage site+HGF were provided in 96-well plates by Spintec Engineering, Aachen,
DE. Supernatants were collected starting one hour after polymerization of the gels, as well as
after 2, 4, 8, 24, 48 and 168 h. At each time point, new medium was added. As described
above (Chapter 2.2.6.3), tPA activates HGF from the silk, therefore 200 ng/ml tPA were added
to the medium in the silk ﬁbroin experiment to check if HGF release was, indeed, enhanced.
2.2.8 Scratch Assay
To analyze the chemotactic eﬀect of HGF on human MSC, as described [Neuss et al., 2004], a
scratch assay, was used. MSC were grown in both compartments of culture-inserts (11.000 cells/
compartment, from ibidi) in 24-well plates (Figure 10). At conﬂuence, inserts were removed
carefully (= 0 h) and stem cell medium (SCM)±HGF (75 ng/ml) was added. Closure of the re-
sulting in vitro wounds was documented photographically at 0, 16 and 24 h after removal of the
inserts. Inserts were used for creating uniform scratch dimensions throughout the experiments.
Each analysis was performed for ﬁve diﬀerent donors.
Figure 10: The inserts were placed in the middle
of the wells of 24-well plates; MSC were seeded into
both compartments. At 80-90% conﬂuency, the in-
serts were carefully removed, SCM±HGF was added
and cells were able to migrate across the deﬁned
scratch for 24 h. Sketch adapted from ibidi, Mar-
tinsried, DE.
2.2.9 Boyden Chamber Assays
Based on the scratch assay results, the eﬀects of HGF incorporated into biomaterials on the
directed MSC migration (chemotaxis) was investigated using four Boyden Chamber Assays:
◆ Classic Assay (Checkerboard Analysis): no biomaterials, ±HGF; used as internal control,
n = 4
◆ Classic Assay with c-Met siRNA transfected MSC, no biomaterials, ±HGF, n = 3
◆ Chemotaxis Assay: biomaterials±HGF placed in the bottom of the wells, n = 5
◆ Chemoinvasion Assay: biomaterials±HGF placed in the bottom of the wells and coated
with a thin layer of Matrigel (+MG) to mimic in vivo situation, n = 5
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Human MSC were seeded in a density of 105 cells/ml in the top compartments of transwell
systems in 24-well plates (Figure 11). The top compartments were separated from the bottom
compartments by polycarbonate membranes with 8 µm pores. Collagen or ﬁbrin gels±HGF
(75 ng/ml) were deposited in the bottom compartment. Plates coated with silk ﬁbroin±tPA
cleavage site±HGF were purchased from Spintec Engineering. In all assays, basal migration (no
biomaterial, no HGF) was used for normalizing values; medium+HGF (75 ng/ml) in the bottom
compartments served as internal control and medium+HGF (75 ng/ml) in the tops served to
exclude chemokinesis. Cells were allowed to migrate for 24 h. After removal of the transwells,
the top cell layers were wiped oﬀ with a lint-free cloth and cut out carefully; membranes were
ﬁxed, stained with Hemacolor
®
and mounted with Vitro Clud
®
. MSC on the bottom sides
of the membranes were quantiﬁed in ﬁve diﬀerent high power ﬁelds per membrane at 200-fold
magniﬁcation. Each analysis was performed in triplicate for ﬁve diﬀerent donors.
Figure 11: Boyden Chamber Assay Sketch. MSC were seeded in medium on top of the membranes (8 µm pore
size). Seventy-ﬁve ng/ml HGF (blue dots) was added either to the medium or to the biomaterials (as shown in
sketch) on the bottom of the wells. After 24 h, top part of the membranes were wiped oﬀ MSC, carefully cut
out of transwells, ﬁxed and HE stained. MSC that migrated through the membranes were quantiﬁed.
2.2.10 In vivo Methods
All in vivo methods were approved by the Landesamt für Natur, Umwelt und Verbraucherschutz
Nordrhein-Westfahlen and by the Animal Care and Use Committee at the University Hospital
Aachen. All in vivo methods were carried out in cooperation with Vera Paefgen who performed
her masters' thesis with on topic of HGF-loaded biomaterials in a murine model: short- and
long-term in vivo reactions [Paefgen, 2013].
Up to four C57BL/6 mice were housed per cage in the Animal Facility of the University
Hospital Aachen and kept under professional care. Water and standard laboratory mouse food
were given ad libitum and mice were maintained on a twelve hour light/dark cycle. Sixty-three
male mice between 20 and 25 grams at the time point of arrival were divided into groups of
three animals for each biomaterial±HGF and for three diﬀerent time points. Time points were
chosen to evaluate cellular responses towards the biomaterials in phases of acute (1 week) and
progressed inﬂammation (3 weeks) as well as late wound healing (12 weeks, Table 6).
All operation procedures were performed under general anesthesia, a mixture of 0.9% NaCl,
10% ketamine and 2% xylazine (intraperitoneal 10 µl/g body weight). Five minutes after
injection, depth of narcosis was conﬁrmed with toe-pinch reﬂex. If mice withdrew their foot, a
further injection of anesthetics (approx. 10-20% of ﬁrst dosage) was given. The fur between
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Table 6: Amount of C57BL/6 mice for in vivo approach
1 week 3 weeks 12 weeks Total number
per biomaterial
Sham 3 3 3 9
Collagen 3 3 3 9
Collagen+HGF 3 3 3 9
Fibrin 3 3 3 9
Fibrin+HGF 3 3 3 9
Silk ﬁbroin 3 3 3 9
Silk ﬁbroin+tPA cleavage site+HGF 3 3 3 9
Total number per time point 21 21 21 63
the shoulder blades and the tail hairline was shaved and eyes were covered with a dexpanthenol
containing ointment to prevent eyes from drying out. Remaining stubbles of fur were gently
removed with a chemical depilatory lotion; mice were rinsed with warm water, toweled and skin
was sanitized with 70% ethanol.
Mice were kept on a heating plate at 37 ○C to stabilize body temperature during operation.
Two incisions on the left and right hand side of the back were made, subcutaneous pockets were
prepared via blunt dissection and biomaterials were implanted. For sham mice, only the pockets
were prepared. Incisions were treated with povidone-iodine solution to prevent infection and
closed with 9 mm wound clips. Mice received 500 µl isotonic NaCl solution subcutaneously,
4 µl/g analgesics intraperitoneal (2.5% carprofen in NaCl) and kept under observation and
infrared heating until end of narcosis. Animals were checked on daily the ﬁrst three days after
operation and weighted two days after surgery. Afterwards, weight was recorded once per
week. All clips were removed after one week. Animals were sacriﬁced after 1, 3 and 12 weeks
by inhalation of isoﬂuorane before cervical dislocation. The regions of incisions or scars from
surgery plus the biomaterial and surrounding tissue were explanted and ﬁxed in 4% formaldehyde
for further histology, immunohistochemistry and immunoﬂuorescence (Chapters 2.2.11, 2.2.11
and 2.2.13). Photos of incisions, scars, healed skin and implants were taken for documentary
purposes.
2.2.11 Histology and Immunohistochemistry
After dehydration, all tissue samples were embedded in paraﬃn and cut with a rotating micro-
tome (Leica, Wetzlar, DE) at 3 µm thickness.
Hematoxylin and Eosin Staining
One well established and routinely used histological staining in the medical clinics is the hema-
toxylin and eosin (HE) staining. It quickly delivers an overview of the samples. Hematoxylin
is an alkaline dye which gives the nuclei a blue color, while the counterpart, the acidic eosin,
stains the cytoplasm in a reddish color. Table 7 summarizes the procedure.
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Table 7: HE staining protocol
Reagent Time in minutes
Xylol 30
Ethanol 100%, 96%, 70% Each 10
Aqua dest. Dipped
Hemalaun (ready to use) 10
Tap water 5-10
Eosin Y (ready to use) 0.75-1
Aqua dest. 1
Ethanol 70%, 96%, 100% Each 10
Xylol 5-10
Vitro-Clud
®
Mounted
Elastica van Gieson Staining
Elastica van Gieson (EVG) is a diﬀerential staining of picric acid and acid fuchsin used to dis-
tinguish between collagen and other connective tissue components. Nuclei show a brown/black
color while collagen ﬁbers (ﬁbrous connective tissue) are stained in pink. Table 8 summarizes
the staining protocol according to the protocol from the Institute of Pathology.
Table 8: EVG staining protocol
Reagent Time in minutes
Xylol 30
Ethanol 100%, 96%, 70% Each 10
Aqua dest. 5
Resorcin fuchsin (ready to use) 15
Tap water 1
Ethanol 80% 1
Tap water 1
Weigert's hematoxylin A + B (in equal parts; A: 1% hematoxylin in 100% 5
ethanol, B: 29% iron chloride and 37% hydrochloric acid in aqua dest.)
Tap water 1
0.5% HCl in ethanol 1
Tap water 1
Picro fuchsin (1% acid fuchsin in cold saturated ﬁltrated picric acid) 3
Tap water 1
Ethanol 70%, 96% Dipped
Ethanol 100% 2 x 1, 2 x 2
Xylol 2 x 2, 2 x 3
Vitro-Clud
®
Mounted
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Immunohistochemistry The principle of immunohistochemistry is the identiﬁcation and his-
tological localization of substances with the help of an antigen-antibody reaction. Immunohis-
tochemical analysis was performed using primary antibodies speciﬁc for CD20, CD117 (both
polyclonal rabbit anti-mouse, 1:800) and CD68 (monoclonal rat anti-mouse, 1:500). Antigen
retrieval was achieved by microwave pre-treatment in citrate buﬀer (pH 6.0). All slides were
stained with the use of an autostainer for immunohistochemistry and the Dako REAL

De-
tection System K5001 HRP/Dab+, rabbit/mouse kit (Dako) according to the manufacturer's
recommendation. The whole protocol is summarized in Table 9. Functionality of the secondary
antibodies was tested in advance.
Table 9: Immunohistochemistry staining protocol
Reagent Time in minutes
Xylol 30
Ethanol 100%, 96%, 70% Each 10
Aqua dest. Dipped
Citrate buﬀer (pH 6.0) 30
Tap water 10
Primary antibodies in diluent 30
Secondary antibodies 15
StreptABC complex/HRP 15
DAB+ 2 x 5
Hematoxylin 5
Aqua dest. 1
Ethanol 70%, 96%, 100% Each 10
Xylol 5-10
Vitro-Clud
®
Mounted
2.2.12 Histological and Immunohistochemical Quantiﬁcation
All quantiﬁcations regarding lymphocytes (CD20), macrophages (CD68), mast cells (CD117),
granulocytes (HE) and neo-vascularization (EVG) were carried out by Vera Paefgen. After
digitizing slides (NanoZoomer 2.0 HT slide scanner, Hamamatsu, JP), ﬁve high power ﬁelds
were chosen which were tried to be distributed as evenly as possible across the area of bio-
material/tissue interface. One high power ﬁeld was approx. 0.394 mm2 (Figure 12). Two high
power ﬁelds were deﬁned on each side of the biomaterial, two ﬁelds at the biomaterial/tissue
interface on the bottom of the implant towards the ventral part and one was located on the
interface on top of the implant towards the dorsal side of the mouse. The distribution of
the ﬁelds was feasible for the silk implants. The collagen gels changed their shape (see also
Figures 34, 39), therefore the location of the ﬁve high power ﬁelds varied. Only cells with a
higher intensity of color compared to the background were counted; cell morphology, size and
cytoplasm-to-nucleus-ratio needed to be comparable to literature [Murphy, 2011]. Fibrin was
not included in quantiﬁcation due to its rapid degradation between six to eight days.
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Figure 12: Distribution of ﬁve high power ﬁelds, representative for all silk samples. HE staining of silk after
three weeks of implantation. High power ﬁelds were evenly distributed across the biomaterial, two ﬁelds at each
end of the material, two ﬁelds at the biomaterial/cell interface located ventrally and one ﬁeld at the interface
located dorsally. Scale bar = 4 mm. Picture taken from [Paefgen, 2013].
2.2.13 Immunoﬂuorescenct Stainings and Quantiﬁcation
Immunoﬂuorescent stainings were performed using antibodies speciﬁc for c-Met (rabbit anti-
mouse) and nucleostemin (goat anti-mouse) and counter-stained with DAPI to visualize endo-
genous murine MSC. Secondary antibodies were speciﬁc for primary antibodies (Chapter 2.1.6).
The staining protocol for c-Met and nucleostemin was adapted from [Neuss et al., 2004] and
summarized in Table 10. Three samples were investigated per condition, where possible they
were taken from three diﬀerent animals. Fluorescent photographs were taken with a microscope
(Leica DM IL) for ﬁve diﬀerent ﬁelds of view . All cover-slips were sealed with nail polish to
prevent drying. Slides were stored in the dark at 4 ○C.
All cells that were positive for c-Met (FITC-labeled) and nucleostemin (Northern Lights
557-labeled) were quantiﬁed. For the course of this study, they will be referred to as double-
colored cells. The quantiﬁcations regarding double-colored cells were carried out in ﬁve high
power ﬁelds per sample at 200-fold magniﬁcation, distributed as shown above (Figure 12).
Analysis was conducted in a blinded fashion by three diﬀerent investigators for three diﬀerent
samples per condition. Since the implants constituted large areas in the tissues which was not
the case in the sham animals, the quantiﬁed numbers were depicted as mean values per high
power ﬁeld. This way, a precise comparison between collagen and silk ﬁbroin was ensured.
2.2.14 Statistical Analysis
Data were presented as mean values±standard deviation (SD) or mean values±standard error
of means (SEM). One-way ANOVA and Tukey's or Bernoulli post test or student t-test were
used for statistical analysis; signiﬁcance was deﬁned as *p < 0.05. The corresponding graphical
representations were generated with GraphPad Prism

6.0.
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Table 10: Immunoﬂuorescence staining protocol for c-Met and nucleostemin
Reagent Time in minutes
Xylol 3 x 5 (on rocker)
Ethanol 100% 3 x 5 (on rocker)
Ethanol 96% 2 x 2 (on rocker)
Ethanol 70% 2 (on rocker)
Puriﬁed water 5
Citrate buﬀer (pH 6.0) 30
Primary antibody + blocking peptide in PBS (other samples in 240 at RT or
PBS; only for c-Met negative control) overnight at 4 ○C
Wash Buﬀer (PBSSA = 0.5% BSA in PBS) 3
Blocking Buﬀer (5% BSA in PBS) 15
Primary antibody (nucleostemin) 1:50 in PBSSA-NP-40 45
PBSSA 3 x 3
Secondary antibody (Northern Lights 557) 1:200 in PBSSA 30 (in the dark)
(all following steps in the dark)
PBSSA 3 x 3
Primary antibody (c-Met) 1:50 in PBSSA-NP-40 45
PBSSA 3 x 3
Secondary antibody (immunoglobulins/biotinylated) 1:250 in PBSSA 30
PBSSA 3 x 3
Streptavidin-FITC 1:250 in PBSSA 30
PBSSA 3 x 3
DAPI 1:50 in puriﬁed water 5
PBSSA 3 x 5
Immu-Mount

Mounted
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3 Results
3.1 Culture of Human Mesenchymal Stem Cells
After their isolation from human bone marrow, MSC were seeded and expanded on tissue
culture plastic. Their proliferation was measured with a colorimetric assay (XTT test). For
this, their supernatant was taken at deﬁned time points (1, 3, 7, 14 days after seeding) and
absorption was measured photometrically at a wavelength of 492 nm. In this assay, absorption
was approximately proportional to cell numbers. The growth curves and doubling times were
determined by using the exponential growth equation
Nt = N0 ∗ eµ∗t (2)
with Nt as the number of cells at a given time point, N0 as the initial number of cells, µ as
the growth rate per day and t as the given time period in days. By converting the equation,
the doubling time (TD) was calculated with
TD = ln2
µ
. (3)
Proliferation of all MSC donors increased within two weeks and doubling time of all donor MSC
(n = 5) was calculated to be between 7 and 12 days (Figure 13).
Figure 13: Proliferation of MSC. Absorption
was measured photometrically for ﬁve diﬀer-
ent MSC donors (n = 5) at 492 nm after 1,
3, 7 and 14 days of seeding. Proliferation of
all MSC donors increased within two weeks of
culture. Depicted are mean values±SD.
3.2 Characterization of Human Mesenchymal Stem Cells
In 2005 and 2006, the International Society for Cellular Therapy published two position pa-
pers stating minimal criteria for the characterization of MSC which are accepted by stem cell
researchers worldwide [Horwitz et al., 2005; Dominici et al., 2006]:◆ Plastic adherent growth
◆ Expression of the surface antigens CD73, CD90, CD105 (positivity ≥ 95% +)
◆ No expression of the surface antigens CD14 or CD11b, CD34, CD45, CD79α or CD19
and HLA class II (positivity ≤ 2% +)
◆ Diﬀerentiation into osteoblasts, adipocytes and chondrocytes in vitro
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Their well-spread morphology and plastic adherence are depicted in Figure 14. All characteri-
zations (Chapters 3.2.1 to 3.2.4) were carried out for three to ﬁve diﬀerent donors between
passages two to ﬁve.
Figure 14: Plastic adherent growth of
MSC. Cells spread across the surface
and showed the typical ﬁbroblast-like
morphology. One exemplary donor of
n ≥ 3. Scale bar = 200 µm.
3.2.1 Surface Marker Expression
Expression of surface markers was analyzed with ﬂow cytometry. All MSC expressed CD73,
CD90 and CD105, but did not express the hematopoietic markers CD34 and CD45. Figure 15
shows the expression of surface markers of one donor exemplarily. Table 11 summarizes all
surface marker expression values (positivity in %) for each donor as well as the mean value
(Xmean) of all ﬁve donors between passages two and four. Xmean showed nearly zero expression
of CD34 and CD45 and over 98% expression of CD73 and CD90. CD105 expression was diverse.
Table 11: Surface marker expression (positivity in %) of MSC donors (n = 5).
CD34+ [%] CD45+ [%] CD73+ [%] CD90+ [%] CD105+ [%]
MSC1 0.10 0.00 99.80 99.80 38.20
MSC2 0.00 0.10 99.90 93.50 96.00
MSC3 0.00 0.00 100.00 100.00 4.00
MSC4 0.00 0.00 100.00 99.50 9.10
MSC5 0.00 0.00 100.00 99.30 2.80
Xmean 0.02 0.02 99.94 98.22 30.02±SEM ±0.02 ±0.02 ±0.04 ±1.2 ±17.71
3.2.2 Osteogenic Diﬀerentiation
According to the protocols from Haynesworth et al. and Pittenger et al., osteogenic diﬀeren-
tiation was induced with osteogenic induction medium [Haynesworth et al., 1992; Pittenger
et al., 1999]. Samples were stained after 7, 14 and 21 days with Alizarin Red showing cal-
cium accumulations typically produced by osteoblasts (Figure 16). Subsequently, Alizarin Red
staining was quantiﬁed. The dye was dissolved and absorption was measured photometrically
at 405 nm. All values were normalized to the corresponding week in SCM.
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Figure 15: Surface marker expression of one MSC donor exemplarily. Grey graph: unlabeled control MSC,
white graph: marker-labeled MSC. The hematopoietic markers CD34 and CD45 were not expressed (upper
panel, positivity ≤ 2% +). CD73, CD90 and CD105 (lower panel, positivity ≥ 95% +) were expressed.
Signiﬁcantly higher absorption values were found under osteogenic conditions compared to
controls in SCM for each time point (after seven days about 1.3-fold higher, after 14 days
about 2.2-fold higher, after 21 days about 3.9-fold higher, Figure 17). The results indicate a
diﬀerentiation of MSC into osteoblasts.
Figure 16: Alizarin Red staining after 7, 14, 21 days of osteogenic diﬀerentiation. Calcium accumulations
(in red) were clearly visible after all time points under diﬀerentiation stimuli (upper panel), indicating that
MSC diﬀerentiated into osteoblasts. MSC in stem cell medium (SCM) served as control (lower panel). Scale
bars = 200 µm.
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Figure 17: Absorption values of Alizarin Red
dye of osteogenic-induced MSC were signiﬁ-
cantly enhanced after 7, 14, 21 days compared
to corresponding controls (SCM). Depicted are
mean values±SEM for n = 4, *p < 0.05.
3.2.3 Adipogenic Diﬀerentiation
Adipogenic diﬀerentiation was induced with adipogenic induction medium and alternated with
adipogenic maintenance medium for 21 days. Presence of lipid vacuoles produced by adipocytes
was conﬁrmed by Oil Red O staining after 14 and 21 days (Figure 18). The results indicate
MSC diﬀerentiation into adipocytes.
Figure 18: Oil Red O staining after 14
and 21 days of adipogenic diﬀerentiation.
Lipid vacuoles were distinctive (red, up-
per panel) after diﬀerentiation at both
time points, indicating that MSC diﬀeren-
tiated into adipocytes. MSC in SCM
served as control (lower panel). Scale
bars = 100 µm.
3.2.4 Chondrogenic Diﬀerentiation
Chondrogenic diﬀerentiation was induced with chondrogenic induction medium. MSC were
cultured in cell pellets and stained with Toluidine Blue after 21 days. Proteoglycans produced
by chondrocytes stained blue (Figure 19). It was not possible to recover any cell pellets after
seven and 14 days and control cell pellets after 21 days due to the fragility of the pellets.
Nevertheless, the results indicate that MSC diﬀerentiated into chondrocytes.
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Figure 19: Toluidine Blue stai-
ning after 21 days of chondro-
genic diﬀerentiation. Proteoglycans
were stained in blue, indicating that
MSC diﬀerentiated into chondro-
cytes. Scale bars = 100 µm (left)
and 200 µm (right).
3.3 C-Met Expression of Mesenchymal Stem Cells
C-Met is the HGF receptor which is expressed on MSC and other cell types. HGF/c-Met
signaling is associated with cell motility and migration. C-Met presence was analyzed for four
diﬀerent MSC donors with PCR and gel electrophoresis. All MSC donors expressed the HGF
receptor c-Met (440 base pairs, Figure 20). β-actin (400 base pairs) was used as housekeeping
gene (data not shown).
Figure 20: PCR of c-Met (440 bp) for four
MSC donors (1-4). The HGF receptor c -Met
was expressed in all donors. L1, L2: Ladder 1, 2
(100 bp); Neg: Negative control = water.
C-Met expression can be down-regulated by RNA interference which was carried out with
c-met siRNA transfection. Cell morphology during RNA silencing was documented photographi-
cally after 24, 48 and 72 hours (h, Figure 21). The negative control (empty vector) did not
exert any inﬂuence on MSC morphology. Non-transfected MSC from the same donor served as
control and showed spindle-shaped morphology as is usual for plastic adherent MSC (see also
Figure 14). The positive control (apoptosis, provided by the kit) resulted in a rounded and
detached cell morphology which is common in apoptotic cells. MSC transfected with c-Met
siRNA showed the same morphology as non-transfected MSC, but were not as conﬂuent.
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Figure 21: C-Met siRNA transfection of one donor shown exemplarily after 24, 48 and 72 h. Neg Ctr:
transfection with empty vector, MSC: non-transfected MSC, Pos Ctr: apoptotic control, siRNA: MSC transfected
with c-Met siRNA. Neg Ctr and non-transfected MSC showed similar cell morphology. Pos Ctr revealed mostly
apoptotic cells, especially after 72 h. MSC transfected with c-Met siRNA showed ﬁbroblast-like morphology,
but were not as conﬂuent as their non-transfected counterparts; n = 3, scale bar = 200 µm (for all pictures).
MSC from the c-Met siRNA transfection approach after 72 h were further analyzed regarding
c-Met gene expression with PCR and gel electrophoresis (Figure 22). Expression of the HGF
receptor c-Met was found in non-transfected MSC as well as in the positive control (apoptotic)
at approximately 440 base pairs, while the c-Met siRNA transfected MSC did not show an
expression of the HGF receptor.
Figure 22: PCR of c-Met of trans-
fected and non-transfected MSC. L: Lad-
der (100 bp); Neg: MSC transfected
with empty vector; MSC: non-transfected
MSC; Pos: apoptotic control; siRNA:
MSC transfected with siRNA. Expression
of HGF receptor c-Met (white bands) at
440 bp only in non-transfected MSC and
positive control.
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3.4 Biomaterial Preparation
For the preparation of collagen and ﬁbrin gels the protocols established by our group were
followed [Neuss et al., 2009b; van de Kamp et al., 2012]. Collagen solution±HGF, polymerized
in Cell Crowns with a diameter of 15 mm and a height of about 10 mm, showed a gel-
like appearance after polymerization. Fibrin±HGF, polymerized in ibidi scratch inserts without
partition wall with dimensions of 9 mm x 9 mm and a height of about 7 mm, also appeared gel-
like. Fibrin was frozen at -20 ○C until use. Silk ﬁbroin membranes±tPA cleavage site±HGF with a
diameter of approx. 6 mm and a thickness of about 200-300 µm were produced by Spintec Engi-
neering, Aachen through genetic engineering of the silkworm Bombyx mori (Chapter 2.2.6.3).
All three biomaterials were usable for in vitro and in vivo experiments (Figure 23).
Figure 23: Preparation of biomaterials. A: collagen gel in Cell Crown after polymerization, B: ﬁbrin gel after
polymerization and freezing, C: silk ﬁbroin membranes produced by Spintec Engineering. All three biomaterials
were usable for in vitro and in vivo experiments.
3.5 HGF Release from Biomaterials
Release of HGF from collagen and ﬁbrin gels was investigated with an HGF ELISA (n = 3).
Seventy-ﬁve ng/ml HGF were incorporated into collagen and ﬁbrin gels. HGF was released over
the period of 168 h (Figure 24). During the ﬁrst eight hours, HGF was released in a burst-like
fashion (approx. 22% of total HGF). Afterwards, HGF was released in a more gradual way.
After 168 h, approx. 33-40% of total HGF was released from both gels.
Figure 24: HGF release from collagen (gray line) and
ﬁbrin (black line) gels after 0, 8, 24, 48 and 168 h.
HGF was released in a burst-like fashion during the ﬁrst
eight hours. Then, HGF was released in a more gra-
dual way from both biomaterials. Depicted are mean
values±SEM for n = 3.
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HGF ELISA was carried out for HGF-loaded silk ﬁbroin membranes with and without tPA
cleavage site in the presence of 200 ng/ml tPA in medium twice. HGF was released from both
membranes in a burst-like manner during the ﬁrst eight hours (up to 20 pg/ml) and then in
a gradual way reaching maximal 30 pg/ml after 168 h (Figure 25). Of note is the unit of
measurement for silk ﬁbroin experiments (1000-fold lower than for collagen and ﬁbrin).
Figure 25: HGF release from silk ﬁbroin+tPA
cleavage site+HGF (gray line) and silk ﬁbroin+HGF
(black line) in medium+tPA after 0, 8, 24, 48 and
168 h. HGF was released in a burst like manner
during the ﬁrst eight hours and more gradual after-
wards until 168 h. Depicted are mean values±SEM
for n = 2. The detection limit of this ELISA
was < 3 pg/ml.
3.6 Scratch Assay
To evaluate the chemotactic eﬀect of HGF on MSC, cell migration assays across a deﬁned
scratch of 500±50 µm were carried out. Based on the paper by Neuss and colleagues, who
determined the best HGF concentration for cell migration to be between 50-100 ng/ml, we
chose 75 ng/ml for all experiments [Neuss et al., 2004]. MSC from four diﬀerent donors were
seeded in culture inserts; at conﬂuence, inserts were removed (= 0 h) and medium+HGF was
added. Medium without HGF served as control. MSC migration was photographed at 0, 16
and 24 h after removal of the inserts (Figure 26). A slight diﬀerence for MSC cultured in
medium+HGF compared to control cells was visible after 16 h. After 24 h, approx. 50% of
the scratch area was covered in the presence of HGF, while the HGF-free counterparts showed
coverage of about 25% of initial cell free area.
Figure 26: Scratch
Assay for one of four
donors exemplarily after
0, 16 and 24 h. MSC
in medium+HGF (lower
panel) closed about twice
as much cell-free area than
their HGF-free counter-
parts (upper panel). Scale
bars = 200 µm.
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3.7 Boyden Chamber Assays
For analysis of directed cell migration (chemotaxis) and random movement (chemokinesis),
MSC were seeded in a density of 105 cells/ml in the top compartments of transwell systems
in 24-well plates. After 24 h, MSC (stained in purple) were clearly distinguishable from the
membrane pores (white circles, Figure 27). For quantiﬁcation, MSC were HE stained and
counted in ﬁve diﬀerent high power ﬁelds at 200-fold magniﬁcation.
Figure 27: HE staining of one exemplary donor
in Classic Boyden Chamber Assay after migra-
ting for 24 h. The membrane pores of 8 µm (white
circles) and the MSC (deep purple) were clearly
distinguishable. Scale bar = 200 µm.
Four Boyden Chamber Assay approaches were used:
◆ Classic Assay (Checkerboard Analysis): no biomaterials, ±HGF; used as internal control,
n = 4
◆ Classic Assay with c-Met siRNA transfected MSC, no biomaterials, ±HGF, n = 3
◆ Chemotaxis Assay: biomaterials±HGF placed in the bottom of the wells, n = 5
◆ Chemoinvasion Assay: biomaterials±HGF coated with a thin layer of Matrigel (+MG)
to mimic in vivo situation, n = 5
Checkerboard Analysis To distinguish between the chemotactic and chemokinetic eﬀects
of a growth factor on motility and migration of MSC, a checkerboard analysis was performed.
No addition of HGF to the top or to the bottom compartments of the transwells was referred
to as basal migration (top/bottom = 0/0). All values were normalized to basal migration.
Addition of HGF to the medium on the bottom (0/75) led to a signiﬁcant increase in MSC
migration compared to (i) basal migration (0/0, about 1.3-fold), (ii) HGF on top (75/0, about
1.5-fold) and (iii) HGF on top and in bottom simultaneously (75/75, about 1.3-fold, Figure 28).
In all following assays, HGF in bottom compartments (0/75) served as internal control.
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Figure 28: Checkerboard Analysis for MSC in
medium±HGF after 24 h. All values were normalized
to basal migration (0/0). The presence of 75 ng/ml
HGF in medium on the bottom (0/75) led to a signiﬁ-
cant increase in MSC migration compared to all other
conditions. Depicted are mean±SEM for n = 4, except
for (75/0): n = 2, *p < 0.05.
Classic Assay with c-Met siRNA Transfected MSC One part of MSC from the same
donors were transfected with c-Met siRNA while the counterpart remained unmodiﬁed. Medium
was either supplemented with HGF or not. In the presence of HGF, non-transfected MSC showed
a signiﬁcantly increase in migration compared to basal migration as well as to their transfected
counterparts (both about 1.4-fold, Figure 29). Migration values for c-Met siRNA transfected
MSC did not vary much in the presence or absence of HGF and was comparable to basal
migration. The results indicate that the HGF receptor c-Met plays a role in MSC motility.
Figure 29: Quantiﬁcation of Classic Assay for
MSC transfected with c-Met siRNA after 24 h.
Medium±HGF was placed in bottom compartment. All
values were normalized to basal migration (0/0). Mi-
gration of MSC was signiﬁcantly enhanced in non-
transfected MSC with HGF while transfected MSC
counterparts showed migration values comparable to
basal migration. The HGF receptor c-Met plays a role
in MSC motility. Depicted are values mean±SEM for
n = 3, *p < 0.05.
Chemotaxis Assay HGF incorporated into collagen and ﬁbrin (placed on the bottom of
the wells) showed signiﬁcantly higher cell migration values (about 1.6-fold and about 1.3-fold,
respectively) than basal migration (0/0, Figure 30, white and gray bars). MSC migration was
signiﬁcantly enhanced in the presence of HGF-loaded silk ﬁbroin and even higher when the tPA
cleavage site was incorporated between the silk ﬁbroin and HGF compared to basal migration
(about 1.3-fold and about 1.5-fold, respectively, Figure 30, black bars).
Chemoinvasion Assay To mimic the in vivo situation of foreign body response after the
implantation of (HGF-loaded) biomaterials, collagen, ﬁbrin and silk ﬁbroin were coated with a
thin layer of Matrigel (+MG). We intentionally coated the biomaterials on the bottom of the well
and not the membrane to investigate a potentially delayed release of HGF. Collagen+HGF+MG
showed a signiﬁcant higher cell migration compared to collagen+MG alone and basal migration
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Figure 30: Quantiﬁcation of Chemotaxis As-
say for collagen gels (white bars), ﬁbrin gels (gray
bars) and silk ﬁbroin (black bars) after 24 h.
All values were normalized to A: basal migra-
tion (0/0). Abbreviations: B: biomaterial only,
C: biomaterial+HGF, D: silk ﬁbroin+tPA clea-
vage site+HGF (only for silk ﬁbroin experiments).
Signiﬁcantly enhanced MSC migration when HGF
was incorporated in all biomaterials. Depicted are
mean±SEM for n = 5, *p < 0.05.
(about 1.2-fold higher, Figure 31, white bars). Fibrin+HGF+MG showed signiﬁcantly higher
cell migration compared to ﬁbrin+MG alone as well as basal migration (both about 1.3-fold
higher, Figure 31, gray bars). Silk ﬁbroin displayed no signiﬁcances in MSC migration. However,
a trend of enhanced MSC migration towards HGF-loaded silk ﬁbroin membranes+MG (with or
without tPA cleavage site, both about 1.2-fold higher) was visible (Figure 31, black bars).
Figure 31: Quantiﬁcation of Chemoinvasion
Assay for collagen gels (white bars), ﬁbrin gels
(gray bars) and silk ﬁbroin (black bars), each
coated with Matrigel (+MG) after 24 h. All
values were normalized to A: basal migration
(0/0). Abbreviations: B: biomaterial+MG, C:
biomaterial+HGF+MG, D: silk ﬁbroin+tPA clea-
vage site+HGF+MG (only for silk ﬁbroin experi-
ments). Signiﬁcantly enhanced MSC migration to-
wards HGF-loaded MG-coated collagen and ﬁbrin
gels. Depicted are mean values±SEM for n = 5,
*p < 0.05.
A comparison between chemotaxis and chemoinvasion assays revealed that MSC migra-
tion towards un-coated collagen±HGF was clearly higher (about 1.3 to 1.4-fold) than towards
their coated opposite. MSC migration towards ﬁbrin remained almost unchanged, indepen-
dent of Matrigel coating. Interestingly, migration towards HGF-loaded silk ﬁbroin membranes
was similar, independent of the MG coating, while MSC migration towards un-coated silk ﬁ-
broin+tPA cleavage site+HGF was about 1.2-fold higher than its coated counterpart.
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3.8 In vivo Implantation
All in vivo experiments were performed together with Vera Paefgen who wrote her Master's
Thesis on short- and long-term in vivo reactions of HGF-loaded biomaterials in a murine model
[Paefgen, 2013]. The same operation procedure was carried out for all groups, for a total of
63 animals. In short, mice were anesthetized, hair was removed, subcutaneous pockets were
prepared and biomaterials were implanted. Sham animals received only the pockets. Incisions
were treated with iodine before clipping close (Figure 32).
Figure 32: Implantation procedure. After anesthesia of mice, A: removing hair, B: making incisions, C: pre-
paring pockets via blunt dissection and implantation of biomaterials±HGF, D: treating incision sites with iodine
before closing with 9 mm wound clips. All mice (n = 63) survived.
All mice survived until sacriﬁce. They were checked on daily for the ﬁrst three days and
weighted two days after the operation; afterwards their weight was recorded once a week to
exclude any abnormal eating habits. All animals lost weight two days after the operation, but
continuously gained weight thereafter (Figure 33).
Figure 33: Weight of mice was documented
at ﬁxed time points. All mice lost weight af-
ter the operation but continuously gained weight
until the day of sacriﬁce. Depicted are mean
values±SEM for n = 21 animals per time point,
*p < 0.05.
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3.9 Macroscopic Views after Biomaterial Explantation
The biomaterials were explanted after one, three and twelve weeks. Collagen was visible and
explantable after all three time points. Macroscopically, more blood vessels were detectable
proximal to collagen+HGF, especially after three weeks (Figure 34 B), but also proximal to
collagen after the ﬁrst week (Figure 34 A). Collagen changed its shape and size depending on
its surrounding and pocket preparation, but independent of HGF (see also Figure 39).
Figure 34: Macroscopic views of A: collagen and B: collagen+HGF explants after one, three and twelve
weeks. After one week, large blood vessels were proximal to collagen implants. After one and three weeks,
vessels were proximal to collagen+HGF implants. Shape and size of collagen and collagen+HGF varied due to
pocket preparation and surrounding. Each image is representative for n = 6 implants per time point.
Silk ﬁbroin was visible and explantable after all three time points. More vessels formed near
to silk ﬁbroin+tPA cleavage site+HGF after three and twelve weeks compared to silk ﬁbroin
alone (Figure 35 A, B). Silk ﬁbroin kept its dimensions throughout all time points.
Figure 35: Macroscopic views of A: silk ﬁbroin and B: silk ﬁbroin+tPA cleavage site+HGF explants after one,
three and twelve weeks. Especially after three and twelve weeks, large blood vessels were visible proximal to silk
ﬁbroin+tPA cleavage site+HGF. Each image is representative for n = 6 implants per time point.
3.10 Histological and Immunohistochemical Analysis
In order to compare cell responses towards biomaterials±HGF and between time points, a
uniform way of quantiﬁcation was established through the deﬁnition of ﬁelds of view. Five
high power ﬁelds with the same surface area were evenly distributed along the implant/tissue
interface of the samples (Figure 12). Positive cells were counted at 200-fold magniﬁcation and
normalized to sham animals according to the corresponding week (further referred to as sham
1w, sham 3w and sham 12w). Fibrin was barely detectable after one week and completely
degraded after three and twelve weeks.
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3.10.1 Anatomy of Murine Skin
Murine skin, like human skin, is composed of the three layers epidermis, dermis and subcutis
(Figure 36). Hair follicles and sebaceous glands are present in the dermis, while sweat glands
are missing. Unlike human skin, a muscle layer (panniculus carnosus) separates the dermis from
the underlying connective tissue and subcutis.
Figure 36: HE staining of unharmed
murine skin. A muscle layer, the panni-
culus carnosus, separates the dermis from
the underlying connective tissue. Bio-
materials were implanted underneath the
muscle layer. Scale bar = 500 µm.
3.10.2 Healing of Incision Sites
After one week, the incision sites were macroscopically (Figure 37) and histologically still visible
in all animals. Usually, the clips were removed after one week, unless they were lost in a ﬁght or
due to inconvenience. These wounds did not heal as well, because the wound itself was larger
and a scab was clearly visible (Figure 37 B). After the ﬁrst week, 3 out of 42 incisions were
comparable to Figure 37 B, the rest was comparable to Figure 37 C and D.
Figure 37: Macroscopic view of in-
cisions after one week in three exem-
plary animals. A: Wound with 9 mm
clip before removal of clip, B: scab due
to ripped oﬀ clip, C: healed and closed
incision, although tissue bulge due to
clip, D: very well-healed incision. Scale
bar = 10 mm for all pictures.
The mice sacriﬁced after three and twelve weeks were again covered by fur which was mostly
like the fur on non-shaved areas. None of the animals from the later time points showed any
open wounds or scabs, but were rather well-covered in fur. Healing of incision sites did not
depend on the biomaterial which was implanted, but on the location of the clip, the amount
of tissue inside clip as well as the behavior of the mouse itself and its cage mates. The healing
process started by accumulation of cells (granulocytes, purple nuclei) in the disrupted tissue
(Figure 38).
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Figure 38: HE staining of sham 1w animal. The
incision site was clearly visible and granulation tis-
sue started to form underneath. The preparation of
the subcutaneous pockets to place the biomaterials
required the disruption of the panniculus carnosus
to reach the connective tissue (sham animals only
received the pockets). Scale bar = 500 µm.
3.10.3 Histological Overview of Biomaterials in vivo
Collagen changed its dimensions due to its gel-like nature, the size of the subcutaneous pockets
and the surrounding (Figure 39). No diﬀerences in cell morphology or cell size were distinguish-
able between HGF-loaded and HGF-free gels as all gels were inﬁltrated by cells. However, more
and more cells invaded the gels with ongoing time. After three weeks, cells were distributed
throughout the whole gels, independent of HGF. After twelve weeks, even higher amounts of
cells were found.
Silk ﬁbroin membranes were covered by a dense cell layer which was most prominent on
the lower side (ventral position) of the implant (Figure 40). Cell morphology revealed a high
nucleus-to-cytoplasm ratio. Silk ﬁbroin was brittle after histological processing, therefore it was
not visible on all slides; but the dense cell layer kept in place, marking the location of the silk
membranes. No cells inﬁltrated the silk ﬁbroin membranes, independent of HGF. The thickness
of the cell layer around the membranes seemed to densify with time but no clear diﬀerences
between HGF-loaded and HGF-free silk ﬁbroin membranes were detectable.
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Figure 39: Size and location of collagen (upper panel) and collagen+HGF (lower panel) implants in HE staining after one, three and twelve weeks in
exemplary animals. Gels highlighted with black dotted lines. Medium to strong cell inﬁltration with ongoing time. Scale bars = 1 mm (left panel), 500 µm
(middle and right panel).
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Figure 40: Size and location of silk ﬁbroin (upper panel) and silk ﬁbroin+tPA cleavage site+HGF (lower panel) implants in HE staining after one, three
and twelve weeks in exemplary animals. Silk ﬁbroin membranes in light pink color. Cell layers surrounding the implants became more dense with ongoing
time. Scale bars = 1 mm (left panel), 250 µm (middle and right panel).
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3.10.4 Formation of Neovascularization
Neovascularization, or angiogenesis, is an important process in wound healing and facilitates
cell migration into the wounded area as well as the transport of nutrients to and waste products
away from the tissue. EVG staining was used to visualize neovascularization in close proximity
to the implants. Only animals implanted with collagen±HGF and silk ﬁbroin±tPA cleavage
site±HGF were quantiﬁed because ﬁbrin±HGF was mostly degraded after six to eight days.
For quantiﬁcation, only blood vessels with a clear round lumen, at least one layer of endo-
thelial cells and at least two erythrocytes were considered. Figure 41 exemplarily shows neo-
vascularization in close proximity to HGF-loaded collagen after three weeks. All values were
normalized to sham 1w, 3w, and 12w (Figure 42).
Figure 41: One exemplary picture
of neovascularization. EVG staining
of collagen+HGF after three weeks.
Blood vessels can be distinguished by
their round shape and the yellow color
of the erythrocytes. Collagen gel high-
lighted with black dotted lines. Scale
bar = 500 µm.
After the ﬁrst week, animals implanted with collagen+HGF and silk ﬁbroin+tPA cleavage
site+HGF showed the highest amount of blood vessels compared to sham 1w (both about
2.3-fold higher, Figure 42 A). After the third week, the majority of blood vessels was formed
proximal to silk ﬁbroin+tPA cleavage site+HGF compared to sham 3w (about 10.8-fold higher),
compared to collagen+HGF (about 6.2-fold higher) and compared to silk ﬁbroin (about 5.8-fold
higher, Figure 42 B). After twelve weeks, neo-vascularization in all animals was largely subsided
and comparable to sham 12w (Figure 42 C) as well as sham 1w.
Figure 42: Quantiﬁcation of neovascularization. A: after one, B: after three, C: after twelve weeks. Abbre-
viations: C: collagen, CH: collagen+HGF, S: silk ﬁbroin, SH: silk ﬁbroin+tPA cleavage site+HGF. After one
week, neovascularization was pronounced in CH and SH implants. After three weeks, implantation of SH resulted
in the highest amount of newly formed blood vessels. Neovascularization subsided after twelve weeks and was
comparable to, or even less than, after one week. Depicted are are mean values of high power ﬁelds±SEM for
n ≥ 18 and normalized to sham 1w, 3w, 12w, *p < 0.05.
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3.10.5 Neutrophil and Eosinophil Granulocytes
Upon wounding, leukocytes are amongst the ﬁrst cells to arrive at the wound site [Epstein
et al., 1999]. Being part of the immune system, leukocytes are formed in the bone marrow and
lymph tissues; in the tissues, their life span is about four to ﬁve days. Upon release of their
granules, which contain numerous enzymes and toxic proteins, leukocytes mount a fast and
powerful defense against pathogenic agents which they mainly destroy through phagocytosis.
The majority of all leukocytes are neutrophils (approx. 62%), while eosinophils make up only
a minority (approx. 2%) [Hall, 2010]. Eosinophils are mainly involved in allergic and hyper-
sensitivity reactions and in the defense against parasites [Murphy, 2011]. Like neutrophils, they
have polymorphous nuclei and their cytoplasm stains intensely red after HE staining. Based on
these features, both neutrophils and eosinophils were quantiﬁed to evaluate cellular responses,
particularly regarding prolonged inﬂammation and infection. For the purpose of this study,
neutrophils and eosinophils were collectively termed granulocytes.
After the ﬁrst week, animals implanted with collagen+HGF and silk ﬁbroin showed compa-
rable amounts of granulocytes and were both about 1.3-fold higher than sham 1w. Granulocyte
numbers were signiﬁcantly enhanced in animals implanted with silk ﬁbroin compared to animals
implanted with collagen (about 0.7-fold, Figure 43 A). After three weeks, granulocytes were
signiﬁcantly enhanced in silk ﬁbroin and silk ﬁbroin+tPA cleavage site+HGF animals compared
to sham 3w (about 11.4-fold and 11.8-fold, respectively). Signiﬁcantly higher values were found
in silk ﬁbroin compared to collagen animals (about 8.8-fold) as well as in silk ﬁbroin+tPA clea-
vage site+HGF animals compared to collagen+HGF (about 8.5-fold, Figure 43 B). After twelve
weeks, the highest amount of granulocytes was found in animals implanted with silk ﬁbroin;
it was signiﬁcantly higher than sham 12w (about 9.4-fold), collagen (about 7.4-fold) and silk
ﬁbroin+tPA cleavage site+HGF (about 6.7-fold). Granulocytes in animals implanted with col-
lagen and collagen+HGF were similar and both were about 2.0- to 2.8-fold higher than sham
12w (Figure 43 C).
Figure 43: Quantiﬁcation of neutrophil and eosinophil granulocytes. A: After one, B: after three, C: after
twelve weeks. Abbreviations: C: collagen, CH: collagen+HGF, S: silk ﬁbroin, SH: silk ﬁbroin+tPA cleavage
site+HGF. Highest amounts of granulocytes were found in S and SH after three weeks and in S after twelve
weeks. Depicted are mean values of high power ﬁelds±SEM for n ≥ 14 and normalized to sham 1w, 3w, 12w,
*p < 0.05.
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3.10.6 B-Lymphocytes
B-lymphocytes and their ally, T-lymphocytes, are part of the adaptive immune system and
originate and mature in the bone marrow. While B-lymphocytes migrate to the lymphoid tissue
throughout the body, T-lymphocytes migrate to the thymus gland [Murphy, 2011]. Both cell
types are needed to mount a speciﬁc immunity against individual pathogens. B-lymphocytes are
part of the bodies' humoral immunity, whereas T-lymphocytes are involved in the bodies' cell-
mediated immunity [Hall, 2010]. At the wound site, B-lymphocytes arrive after the granulocytes.
They are activated upon the encountering of a speciﬁc antigen and start secreting antibodies.
Millions of speciﬁc types of B-lymphocytes exist as each cell is only capable of forming one
speciﬁc antibody and reacting to one antigen in particular [Hall, 2010]. Through the expression
of speciﬁc surface markers, diﬀerent subsets of lymphocytes can be identiﬁed. CD20 is a marker
that is expressed on activated B-lymphocytes.
After the ﬁrst week, animals implanted with silk ﬁbroin showed the highest number of B-
lymphocytes which was signiﬁcantly higher compared to collagen (about 1.5-fold, Figure 44 A).
The amount of B-lymphocytes in animals implanted with collagen+HGF as well as with silk
ﬁbroin+tPA cleavage site+HGF were both comparable to sham 1w. HGF-free collagen elicited
even lower amounts of B-lymphocytes than sham 1w. After three weeks, B-lymphocytes
were comparable to sham 3w for all implanted animals (Figure 44 B). After twelve weeks,
B-lymphocytes were signiﬁcantly increased in collagen and collagen+HGF animals compared to
sham 12w (about 2.6-fold and 3.6-fold, respectively, Figure 44 C). Silk ﬁbroin+tPA cleavage
site+HGF elicited higher B-lymphocyte responses than silk ﬁbroin; they were slightly higher
than after the ﬁrst and third week.
Figure 44: Quantiﬁcation of B-lymphocytes. A: After one, B: after three, C: after twelve weeks. Abbreviations:
C: collagen, CH: collagen+HGF, S: silk ﬁbroin, SH: silk ﬁbroin+tPA cleavage site+HGF. After one week, highest
amount of B-lymphocytes in animals with S. After twelve weeks, signiﬁcantly higher amounts of B-lymphocytes
in animals implanted with C and CH compared to sham 12w. Depicted are mean values of high power ﬁelds±SEM
for n ≥ 17 and normalized to sham 1w, 3w, 12w, *p < 0.05.
3.10.7 Monocytes/Macrophages
Just like granulocytes, monocytes are a subdivision of leukocytes and part of the innate immune
response. They arise from the bone marrow and diﬀerentiate into tissue macrophages in order
to protect the body from foreign matter mainly through phagocytosis [Hall, 2010]. They
also synthesize signaling proteins to recruit other cells of the immune system and constantly
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clear debris from the body [Murphy, 2011]. Tissue macrophages (mature forms of monocytes)
are activated into the wound by diﬀerent growth factors released from the ﬁbrin clot [Martin,
1997]. Circulating monocytes enter the inﬂamed tissue alongside of the neutrophil granulocytes
and diﬀerentiate into macrophages [Murphy, 2011]. They can reside at the wound site for
up to several weeks due to their ability to dispose of the residual products from engulﬁng
large quantities of particles, cells and even neutrophils [Hall, 2010]. CD68 is expressed by
monocytes/macrophages and used as a marker for their quantiﬁcation.
After the ﬁrst week, the amount of monocytes/macrophages was signiﬁcantly higher in ani-
mals implanted with silk ﬁbroin+tPA cleavage site+HGF compared to collagen+HGF (about
0.8-fold). Monocyte/macrophage responses towards collagen, collagen+HGF and silk ﬁbroin
were lower than towards sham 1w (Figure 45 A). After three weeks, cell numbers were signi-
ﬁcantly higher in collagen animals compared to sham 3w (about 2.7-fold). In general, all
values were slightly enhanced compared to the ﬁrst week (Figure 45 B). After twelve weeks,
animals implanted with silk and silk ﬁbroin+tPA cleavage site+HGF showed signiﬁcantly higher
amounts of monocytes/macrophages compared to sham 12w (about 8.0-fold and 8.6-fold,
respectively). Monocytes/macrophages in animals implanted with collagen+HGF, silk ﬁbroin
and silk ﬁbroin+tPA cleavage site+HGF were at least twice as much as after three weeks
(Figure 45 C).
Figure 45: Quantiﬁcation of monocytes/macrophages. A: After one, B: after three, C: after twelve weeks.
Abbreviations: C: collagen, CH: collagen+HGF, S: silk ﬁbroin, SH: silk ﬁbroin+tPA cleavage site+HGF. After
three weeks, high amounts of monocytes/macrophages in animals implanted with C compared to sham 3w.
After twelve weeks, monocyte/macrophage numbers were signiﬁcantly higher in animals implanted with S and
SH in comparison to sham 12w. Depicted are mean values of high power ﬁelds±SEM for n ≥ 15 and normalized
to sham 1w, 3w, 12w, *p < 0.05.
3.10.8 Mast Cells
Mast cells, another part of the immune system, play a key role in the inﬂammatory process,
especially in allergic responses. They are mostly distributed alongside of capillaries [Hall, 2010].
Upon activation, they release histamine- and heparin-rich granules as well as cytokines to
permeabilize blood vessels, thus facilitating ﬂuid entry and mobilization of other immune cells
into the tissues. They express the cell surface marker CD117 (also known as mast/stem cell
growth factor receptor) which was used for their detection.
After the ﬁrst week, the highest amount of mast cells was found in animals implanted with
silk ﬁbroin as well as silk ﬁbroin+tPA cleavage site+HGF compared to sham 1w (about 1.8-
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fold and 2.0-fold, respectively). In animals implanted with collagen and collagen+HGF, the
amount of mast cells was below that of sham 1w. Signiﬁcantly higher mast cell numbers were
found in animals with silk ﬁbroin+tPA cleavage site+HGF compared to collagen+HGF and also
with silk ﬁibroin compared to collagen (both about 1.3-fold, Figure 46 A). After three weeks,
signiﬁcantly higher amounts of mast cells were observed towards silk ﬁbroin+tPA cleavage
site+HGF in comparison to sham 3w and also to silk ﬁbroin (about 2.5-fold and about 1.3-
fold, respectively). The amount of mast cells in collagen implanted animals increased and was
higher compared to sham 3w (about 2.2-fold, Figure 46 B). After twelve weeks, the signiﬁcantly
highest amount of mast cells was found in silk ﬁbroin and silk ﬁbroin+tPA cleavage site+HGF
compared to sham 12w (about 4.5-fold and 3.9-fold, respectively). Mast cell response towards
collagen+HGF was slightly enhanced when compared to their HGF-free counterparts after twelve
weeks. (Figure 46 C).
Figure 46: Quantiﬁcation of mast cells. A: After one, B: after three, C: after twelve weeks. Abbreviations:
C: collagen, CH: collagen+HGF, S: silk ﬁbroin, SH: silk ﬁbroin+tPA cleavage site+HGF. After one week, the
highest amount of mast cells was found in animals implanted with SH compared to sham after each time point.
Depicted are mean values of high power ﬁelds±SEM for n ≥ 18 and normalized to sham 1w, 3w, 12w, *p < 0.05.
3.10.9 Expression of c-Met and Nucleostemin
As HGF is described to mobilize MSC in vitro [Neuss et al., 2004], we investigated if HGF-
loaded biomaterials recruit MSC in vivo to the sites of injury. Due to the lack of one unique in
vivo marker for MSC to date [Horwitz et al., 2005; Dominici et al., 2006; Caplan and Correa,
2011; Rasini et al., 2013], the combination of two antibodies described as potential markers
for murine as well as human MSC seemed suitable: on the one hand, the HGF receptor c-Met,
located on the membrane of MSC [Naldini et al., 1991], on the other hand nucleostemin, a
nucleolar protein [Kaﬁenah et al., 2006]. Both antibodies were labeled with immunoﬂuorescent
dyes; c-Met expression was labeled with FITC, while nucleostemin was coupled to Northern
Lights 557. All samples were counterstained with DAPI to visualize the nucleoli in blue. All
cells that showed expression for the two colors (green and red) were counted. For the course
of this study, they will be referred to as double-colored cells. Examples are shown in medium
and high magniﬁcation in Figure 47. Other cells also express c-Met, for instance epithelial or
endothelial cells, but, to the best of our knowledge, no specialized cells express both markers.
For immunoﬂuorescent analysis, positive cells were not normalized to sham animals, but
mean values per high power ﬁeld were documented. Analysis were carried out in a blinded
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Figure 47: Immunoﬂuorescent staining of murine MSC. Murine MSC were isolated from bone marrow of
C57BL/6 mice and served as control cells for immunoﬂuorescent stainings. Nucleostemin (red) was expressed
in the nucleolus, encircled by a DAPI-stained nucleus (blue); both were surrounded by c-Met, expressed at the
membrane (green). The cells which expressed the two colors green and red were referred to as double-colored
cells and quantiﬁed. Scale bars = 250 µm (left) and 100 µm (right).
fashion by three diﬀerent investigators. After the ﬁrst week, animals implanted with colla-
gen+HGF and silk ﬁbroin+tPA cleavage site+HGF showed similar amounts of double-colored
cells (Figure 48 A). Implantation of collagen+HGF resulted in signiﬁcantly higher amounts
of double-colored cells than implantation of HGF-free collagen (about 4-times higher). Silk
ﬁbroin+tPA cleavage site+HGF resulted in about double the amount of double-colored cells
than silk ﬁbroin without HGF. The amounts of double-colored cells in animals implanted with
HGF-free collagen and HGF-free silk ﬁbroin were comparable. After three weeks, hardly any
double-colored cells were detectable in animals implanted with collagen gels, independent of
HGF. Animals implanted with HGF-presenting silk ﬁbroin showed higher amounts of double-
colored cells than HGF-free silk ﬁbroin (Figure 48 B). After twelve weeks, collagen+HGF as well
as silk ﬁbroin+tPA cleavage site+HGF resulted in the highest amounts of double-colored cells,
compared to the ﬁrst two time points. Collagen+HGF and silk ﬁbroin+tPA cleavage site+HGF
implants resulted in signiﬁcantly higher amounts of double-colored cells than their HGF-devoid
counterparts (about twice and four times as many, respectively, Figure 48 C).
Figure 48: Quantiﬁcation of double-positive cells. A: after one, B: after three and C: after twelve weeks.
Abbreviations: C: collagen, CH: collagen+HGF, S: silk, SH: silk+tPA cleavage site+HGF. Higher amounts of
double-positive cells in animals implanted with CH compared to C after one and twelve weeks. SH elicited higher
cell numbers in comparison to S after all time points. Depicted are mean values of high power ﬁelds±SEM for
n = 10, *p < 0.05.
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4 Discussion
The purpose of this study was to investigate MSC migration and recruitment towards HGF-
loaded biomaterials in vitro and in vivo. Collagen, ﬁbrin and silk ﬁbroin were chosen due to
their advantageous properties in tissue-engineered skin and other ﬁelds of TE [Laurens et al.,
2006; Schneider et al., 2009; Zhang et al., 2008; Elgharably et al., 2013]. Based on our in vitro
and in vivo experiments, the ﬁve main ﬁndings of the present study are:
1. Human MSC can be characterized in vitro according to the minimal criteria proposed by
the International Society for Cellular Therapy
2. HGF can be incorporated into collagen and ﬁbrin gels as well as silk ﬁbroin membranes.
HGF is released in a burst-like manner during the ﬁrst eight hours and then in a gradual
way over at least seven days in vitro
3. Human MSC migrate towards HGF and HGF-loaded biomaterials in vitro. The HGF
receptor c-Met is involved in MSC motility.
4. HGF-loaded and HGF-free collagen and silk ﬁbroin implants elicit low to moderate immune
responses in mice
5. Endogenous MSC are recruited by HGF-loaded biomaterials in a murine model
4.1 Characterization of Human Mesenchymal Stem Cells
MSC can be derived from several diﬀerent sources, such as bone marrow, adipose tissue or
blood [Pittenger et al., 1999; Zuk, 2002; Huang et al., 2009]. To date, there are no unique
markers for their speciﬁc characterization, especially in vivo [Caplan and Correa, 2011; Boxall
and Jones, 2012]. To ensure a common MSC standard between the laboratories worldwide, a
common nomenclature for MSC, based on plastic adherent growth, surface marker expression
and multipotent diﬀerentiation potential, was deﬁned [Horwitz et al., 2005; Dominici et al.,
2006]. We characterized bone-marrow derived MSC from femoral heads of human patients
regarding these properties.
The spindle-shaped morphology of MSC and their plastic adherence (Figure 14) were con-
sistent with the criteria [Dominici et al., 2006], as was the functional proof of multipotency
of MSC though their diﬀerentiation into osteogenic, adipogenic and chondrogenic lineages (Fi-
gures 16, 17, 18, 19) [Pittenger et al., 1999; Neuss et al., 2004]. Flow cytometric analysis of
ﬁve diﬀerent MSC donors revealed very low expression of the hematopoietic markers CD34 and
CD45, but high positive expression of CD73 and CD90 (Figure 15, Table 11), which all meet
the criteria [Dominici et al., 2006]. CD105-positivity was on average about 30% with a high
standard error of means between the donors (Figure 15, Table 11). On the one hand, this might
be attributed to the strong donor variance or the relatively old age of the donors (60 to 85
years). Signiﬁcant age-related changes in the expression of markers such as Stro-1 and CD105
can occur and aging is accompanied by a decline in frequency, diﬀerentiation and expansion
potential of MSC; however it is not completely understood to what extent [Kern et al., 2006;
Stolzing et al., 2008; Roobrouck et al., 2008]. The age-related change in CD105 expression was
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also indicated by our calculated doubling time of about seven days in vitro (Figure 13), which
is at least twice as much as described (1.375 to 4 days, depending on the passage) [Conget and
Minguell, 1999; Sekiya et al., 2002; Lee et al., 2004]. On the other hand, the phenotypically
heterogeneous cell population of isolated MSC [Chamberlain et al., 2007] as well as diﬀerent
colony sizes and cell morphologies might eﬀect the varying growth or diﬀerentiation behavior
into a certain lineage [Bianco and Robey, 2001].
In summary, all of the criteria established by the International Society for Cellular Therapy
were met by the bone-marrow derived MSC isolated in our laboratory and they were used for
subsequent in vitro experiments. The isolation of homogenous cell populations is, of course,
preferable; however overcoming the limitations of selective MSC antibodies shortage, age-
dependent expansion as well as hampered diﬀerentiation based on the cell source is not yet
in reach. Promising strategies to purify MSC are based on their surface marker expression
[Bühring et al., 2007; Gang et al., 2007]. Understanding MSC biology is vital for the isolation
and utilization of cell sources for the purposes of cell therapies and Regenerative Medicine.
4.2 HGF Release from Biomaterials
The delivery of drugs and biological molecules has been a ﬁeld of intensive investigation for many
years, with special interest in the controlled spatio-temporal delivery of therapeutics. In the
majority of cases, polymeric systems (e.g. alginate hydrogels, microspheres or PLGA scaﬀolds)
for drug delivery are utilized because their material characteristics can be manipulated relatively
easy [Naderi et al., 2011]. In this study, however, we used three natural biomaterials collagen,
ﬁbrin and silk ﬁbroin. HGF was chosen for this project because of its mitogenic and motogenic
eﬀect on epithelial, endothelial cells, keratinocytes and MSC [Bussolino et al., 1992; Matsumoto
and Nakamura, 1996; Ding, 2003; Neuss et al., 2004] and HGF was combined with collagen,
ﬁbrin or silk ﬁbroin to investigate in vitro release.
Release kinetics of cytokines from materials as well as cell behavior strongly depend on
the source, structure, composition and manufacturing of the biomaterial, the technique of
immobilizing (e.g. chemical conjugation, physical encapsulation, release on demand) as well
as the characteristics of the molecules (molecular weight, binding aﬃnity etc.) [Lee et al.,
2001; Wong et al., 2003; Kumar et al., 2004; Lee et al., 2010b]. Generally, the fastest release
is achieved by a loosely connected ﬁbrillar network with a low viscosity while higher retention
rates are generated via cross-linking or other physico-chemical methods [Friess, 1998].
Certainly, in vitro approaches can only roughly represent the complex and well-orchestrated
in vivo environment. The natural micro-milieu, physiological changes, intrinsic mechanisms
and possibly still unknown eﬀects might inﬂuence release and degradation behavior in vivo
[Boer et al., 2010]. Nonetheless, using in vitro data is a common step to predict in vivo
bio-performance of a molecule in drug development [Dash et al., 2010].
4.2.1 Collagen and Fibrin Gels
Collagen and ﬁbrin inherit excellent characteristics, such as biocompatibility, low immune res-
ponse, comparatively fast degradability in vivo as well as extensive forming and modiﬁcation
potential [Lee et al., 2001; Spotnitz, 2010]. Several studies showed promising results for growth
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factor-loaded collagen and ﬁbrin scaﬀolds. For instance, EGF-loaded collagen sponges increased
epithelialization and simultaneously decreased wound contraction compared to the sponges or
the growth factor alone in a rabbit model of full-thickness excisional wounds [Inoue et al.,
1998]. Similar eﬀects were shown for bFGF-loaded collagen sponges in a delayed healing model
in rabbits [Ono et al., 1999]. Very recently, neurotensin-loaded collagen matrices reduced
inﬂammation and improved wound healing in a diabetic mouse model [Moura et al., 2014].
Beside wound healing, the ﬁelds of periodontics and ophthalmology [Friess, 1998] or bone
formation [Wallace and Rosenblatt, 2003] can proﬁt from collagen-based delivery vehicles.
In case of ﬁbrin, FGF-1/ﬁbrin scaﬀolds improved angiogenesis, ﬁbroblastic responses and en-
hanced mechanical properties compared to untreated controls in an early study of full-thickness
wounds in rabbits [Pandit et al., 2000]. More recently, a ﬁbrin-based scaﬀold loaded simul-
taneously with VEGF and bFGF resulted in complete re-epithelialization in a diabetic mouse
model [Losi et al., 2013]. Besides its commercial and FDA-approved uses as a sealant and glue,
ﬁbrin-based delivery systems have been attested to be beneﬁcial for the TE of cartilage, nerve,
skin and cardiac tissues [Rajangam and An, 2013].
HGF was incorporated before polymerization of collagen and ﬁbrin gels. It was released
quickly during the ﬁrst eight hours and in a gradual way afterwards until day seven (Figure 24).
Similar results were reported for HGF released from bovine acellular scaﬀolds fabricated from
the lamina propria as well as from collagen type I-based vitriﬁed membrane [Xu et al., 2009;
Magjarevic and Jobbágy, 2012].
To our knowledge, no in vitro studies on the release of HGF from ﬁbrin-based materials
were published to this date. However, the release of TGF-β from ﬁbrin glue stabilized with
aprotinin as well as the release of β-nerve growth factor from a heparin-containing ﬁbrin-based
delivery system were both in line to our ﬁndings [Sakiyama-Elbert and Hubbell, 2000; Catelas
et al., 2008].
Based on these results, collagen and ﬁbrin gels delivered HGF in vitro in a way that is
useable for further in vitro experiments with MSC as well as for in vivo investigations.
4.2.2 Silk Fibroin Membranes
Silk ﬁbroin is a relatively recent but up-and-coming biomaterial in the ﬁeld of TE as it exhibits
a range of modiﬁcation possibilities regarding its degradability, surface alteration or geometry
[Vepari and Kaplan, 2007]. So far, silk is seen as a possible delivery vehicle for musculoskeletal
applications or bone and ligament tissue repair [Hofmann et al., 2006; Omenetto and Kaplan,
2010; Meinel and Kaplan, 2012], although the in vivo delivery of therapeutics from silk ﬁbroin
has not been extensively studied.
The silk ﬁbroin membranes used in this project were generated through genetic engineering
of silk worms (Chapter 2.2.6.3). Three diﬀerent membranes were used: one silk ﬁbroin mem-
brane without HGF, one that expressed the fusion protein of ﬁbroin light chain+HGF and one
that expressed the fusion protein of ﬁbroin light chain+tPA cleavage site+HGF (used for all in
vivo experiments). Through the incorporation of the tPA cleavage site, HGF was thought to be
released in higher amounts, because tPA converts HGF from its inactive precursor form into a
bioactive form in vivo [Mars et al., 1993]. In vivo, an elevated expression of tPA during wound
closure was found, suggesting a role in establishing granulation tissue [Grøndahl-Hansen et al.,
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1988]. Furthermore, plasminogen knockout mice were deﬁcient in wound closure, indicating an
essential role of plasminogen in the repair of skin wounds [Rømer et al., 1996]. The expres-
sion of fusion proteins (e.g. human type III collagen, bFGF) from transgenic silk worms was
reported, although the silks were always isolated from the cocoons [Tomita, 2011] and needed
further post-processing [Tomita et al., 2002; Hino et al., 2006].
In our study, both membranes released HGF in lower concentrations than collagen and
ﬁbrin gels (about 1.000-fold, Figure 25). The release was burst-like during the ﬁrst eight
hours and afterwards in a more gradual way. After seven days, each membrane released a
total concentration of about 30 pg/ml of HGF. According to unpublished data from Spintec
Engineering, surface presentations of diﬀerent growth factors from silk ﬁbroin ranged between
0.1 ng/cm2 and 2.6 ng/cm2. For our membranes, this would correspond to about 28.27 to
728.12 pg of HGF per area of each membrane (in 2D). Thirty pg/ml were therefore close to the
lower bound. The similar HGF release from both membranes after seven days was surprising,
since tPA was added to the medium in order to enable active release of HGF through the tPA
cleavage sites. Increasing the number of assays, the experimental time or a change in geometry
might lead to a more pronounced diﬀerence between the membranes.
The only study similar to ours derived a recombinant fusion protein bFGF/ﬁbroin light
chain from cocoons of transgenic silk worms [Hino et al., 2006]. Although the yield of the
expression of the bFGF/ﬁbroin light chain was relatively low (0.04%), its growth-promoting
activity on human umbilical vein endothelial cells after a refolding process was shown in vitro.
A diﬀerent and more simple approach involved the soaking non-transgenic silk ﬁbroin scaﬀolds
in bone morphogenetic protein-2 (BMP-2), leading to an initial burst release of 75% of the
initial amount of BMP-2 from the scaﬀolds after one week in vitro. This was attributed to
diﬀusion through the pores. These BMP-2-loaded scaﬀolds were implanted into a critical size
cranial defect of mice, resulting in enhanced bone healing [Karageorgiou et al., 2006]. Another
study showed the generation of electrospun EGF/silk ﬁbroin mats which could be implemented
as bioactive wound dressings to accelerate re-epithelialization. EGF was released burst-like
during the ﬁrst eight hours, but afterwards gradually in a time-dependent manner until 170 h
(about 25% EGF release) [Schneider et al., 2009]. Although all studies mentioned above are
not entirely comparable to ours, they support our ﬁndings on the feasible production of growth
factor-loaded silk ﬁbroin scaﬀolds and their in vitro release over time.
All in all, the biological activity of HGF was proven with the Boyden Chamber Assays
(Chapter 3.7), indicating suﬃcient HGF release from the silk ﬁbroin membranes to elicit MSC
responses. Our in vitro results hold great potential for further in vivo experiments.
4.3 In vitro Migration of Mesenchymal Stem Cells
The secretion of HGF by MSC and the expression of its receptor c-Met on their surface have
been described [Takai et al., 1997; Neuss et al., 2004; Forte et al., 2006]. MSC are susceptible to
the moto- and mitogenic inﬂuence of HGF, making HGF a promising chemokine for in vitro and
in vivo migration studies. This was demonstrated in a monolayer scratch model by Neuss et al.
who showed MSC migration towards HGF was best at HGF-concentrations of 50 to 100 ng/ml
[Neuss et al., 2004]. MSC are pivotal players in immune responses and wound healing, as shown
for non-healing chronic wounds in humans [Badiavas and Falanga, 2003], corneal wound healing
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in rats [Oh et al., 2008] or delayed wound healing in diabetic rats [Wan et al., 2013]. These
studies suggest a promising eﬀect of MSC in combination with HGF for further experiments.
One well-established, simple and economical tool to measure the chemokinetic (random)
behavior of a certain cell type is the scratch assay (i), a monolayer wound healing model. Its main
advantages are live-cell imaging and tracking of single cells, however establishment of a chemical
gradient is not possible [Liang et al., 2007]. Therefore, the Classic Boyden Chamber Assay
(ii, Checkerboard Analysis) [Boyden, 1962] and two novel adaptations thereof, the chemotaxis
assay (iii) and the chemoinvasion assay (iv) were used. In both adaptations, HGF-loaded or
HGF-free biomaterials were placed on the bottom of transwells and MSC on the top of transwells
to evaluate MSC migration towards a HGF concentration gradient. In the chemoinvasion assay,
a thin layer of Matrigel was added on top of the biomaterials. Chemoinvasion is the migration
of (invasive) cells through a matrix barrier [Albini and Noonan, 2010]. Since Matrigel is a
reconstituted basement membrane, we adopted the term chemoinvasion to distinguish both
experiments from one another. We intentionally coated the biomaterials with Matrigel and not
the membrane to mimic the in vivo situation of ﬁbrous capsule formation and foreign body
response which are host reactions following implantation [Anderson et al., 2008].
(i) In the scratch assay, chemokinetic behavior of MSC resulted in the coverage of approxi-
mately 50% of cell-free area in the presence HGF, while approximately 25% of cell-free area was
covered in HGF-free controls after 24 h (Figure 26). Our ﬁndings show the chemoattractive
inﬂuence of HGF on MSC migration in vitro which is in line with previous studies [Neuss et al.,
2004; Forte et al., 2006; Vogel et al., 2013].
(ii) Checkerboard Analysis was carried out to distinguish the chemotactic (directed) from
the chemokinetic (random) eﬀect of HGF on MSC motility and migration. HGF was added
either to the top, the bottom or to both compartments of the Boyden Chamber. Signiﬁcantly
enhanced migration of MSC took place towards a concentration gradient (HGF in the bottom
compartment), while MSC migration was clearly hampered when HGF was added to the top
compartment (Figure 28). The presence of HGF in both compartments did not exert an
inﬂuence on cell motility or migration behavior. These ﬁndings suggest a strong chemotactic
and very low (if at all) chemokinetic eﬀect of HGF on MSC which is in agreement to previous
studies [Ozaki et al., 2007; Zheng et al., 2013]. The HGF-induced migratory behavior of cells
of non-cancer origin, such as immortalized neurons [Giacobini et al., 2002], vascular smooth
muscle cells [Taher et al., 2002] and pericytes [Liu et al., 2007] also support our results. In
contrast, both eﬀects, chemotactic and chemokinetic, of HGF were reported for human lung-
cancer cells, mesothelioma cells and uveal melanoma cells [Bredin et al., 1999; Harvey et al.,
2000; Woodward et al., 2002]. The widely described over-expression of HGF or c-Met on
cancerous cells, mostly attributed to dysregulation, explains to some extend the high motility
and invasiveness of many tumors [Birchmeier et al., 2003; Ma et al., 2003].
(iii) In the chemotaxis assay, the incorporation of HGF into collagen, ﬁbrin and silk ﬁbroin
resulted in (signiﬁcantly) higher MSC migration compared to HGF-free materials (Figure 30).
HGF-loaded membranes with the fusion protein of ﬁbroin light chain+tPA cleavage site elicited
a signiﬁcant increase in MSC migration in comparison to membranes with the fusion protein of
ﬁbroin light chain+HGF. We think that HGF was converted into its activated form by tPA in
vitro, as described earlier [Mars et al., 1993], thus mobilizing higher numbers of MSC.
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(iv) Higher MSC migration was found towards un-coated biomaterials and HGF than towards
Matrigel-coated biomaterials with HGF, indicating the possibility of a delayed release in the
presence of Matrigel (Figure 31). Beforehand, chemotactic or chemokinetic eﬀects of solely
Matrigel on MSC was excluded (data not shown). To our knowledge, no previous assays with
Matrigel-coated collagen, ﬁbrin or silk ﬁbroin were published. The combination of collagen with
Matrigel supported the growth of diﬀerent cell types, e.g. murine osteocytes and bone marrow
cells as well as epithelial and stromal cells [Kurata et al., 2006; Lü et al., 2009].
By blocking one part of the HGF/c-Met signaling axis, for instance through a tyrosine
kinase inhibitor, a c-Met inhibitor or a neutralizing anti-HGF antibody, inhibition of migration
of diﬀerent cancer cell types and also MSC by was reported [Forte et al., 2006; Matsumoto and
Nakamura, 2006; Holt et al., 2008; Vogel et al., 2013]. The approach of reporter gene knock
down with c-Met siRNA transfection [Shinomiya, 2004] was used here and a Checkerboard
Analysis was carried out. In agreement to Shinomiya et al., MSC migration was signiﬁcantly
inhibited when cells were transfected, even in the presence of HGF, in comparison to their
non-transfected counterparts (Figure 29).
Taken together, this study describes for the ﬁrst time the directed migration of MSC towards
HGF-loaded collagen, ﬁbrin and silk ﬁbroin in vitro. Our ﬁndings underline once more that the
HGF/c-Met pathway is vital for MSC migration in vitro. These results open up new insights
regarding cell motility and growth factor delivery in vitro which will be further investigated in
an in vivo model.
4.4 In vivo Tissue Responses
Evaluation of the tissue responses towards implants is essential to assess their general in vivo
behavior and prove their (bio)compatibility in a natural environment. Especially pivotal for the
translation of medical products from bench to bedside are animal models to verify in vitro results
and mimic human diseases. Murine models are most commonly used, due to their easy handling
and housing, cost eﬃciency, availability and extensively documented mouse genome database
[Wong et al., 2011]. Although they are not able to reproduce the exact pathophysiological
mechanisms of humans and a recent study emphasized a rather poor correlation of mouse
models with human conditions [Seok et al., 2013], we used the general purpose C57BL/6J
mouse strain for the initial in vivo evaluation of the biomaterials.
In brief, the hosts' immune responses after implantation entails the following [Anderson
et al., 2008]: blood/material interactions, thrombus/blood clot formation, acute and chronic
inﬂammation, granulation tissue formation, foreign body reaction and ﬁbrous capsule develop-
ment. Extrinsic and intrinsic coagulation systems are activated, taking part in the control and
promotion of wound healing [Anderson et al., 2008]. Angiogenesis, or neo-vascularization, gene-
rally starts a few days after injury and subsides with the remodeling of the granulation tissue
into scar tissue. [Shaw and Martin, 2009]. Neo-vascularization is one of the main challenges,
because new structures are strongly dependent on a regular blood supply as cells will undergo
apoptosis otherwise [Griﬃth, 2002].
HGF, an intrinsic player in acute and chronic wound healing due to its potential to recruit
immune cells, is also a promoter of vascularization and granulation tissue formation in vivo
[Toyoda et al., 2001; Bevan et al., 2004]. HGF is secreted by MSC and apoptotic cells, although
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its up-regulation is locally variant [Schreml et al., 2010]. In healthy human volunteers, serum
HGF concentrations were reported to be 0.35±0.03 ng/ml [Morishita et al., 1999].
Upon implantation of HGF-loaded biomaterials, the distribution frequencies of immune
cells (neutrophil and eosinophil granulocytes, CD68+ monocytes/macrophages, CD117+ mast
cells, CD20+ B-lymphocytes) and the diﬀerences between acute inﬂammation (after one week
of biomaterial implantation), progressed inﬂammation (after three weeks) and resolution of
wound repair (after twelve weeks) were evaluated. In particular, the diﬀerences between HGF-
loaded and HGF-free biomaterials as well as the general performance of this novel silk ﬁbroin
were of interest. Non-cross-linked collagen was used, based on recent evidence of its advanced
host integration compared to cross-linked collagen [Novitsky et al., 2013]. Fibrin±HGF was not
analyzed in more detail, due to its rapid degradation after six to eight days in vivo.
To the best of our knowledge, this is the ﬁrst study elucidating in vivo behavior of HGF-
loaded non-cross-linked collagen as well as HGF-loaded silk ﬁbroin derived from transgenic
silkworms.
4.4.1 Collagen Implants
One week after implantation, all collagen gels were easily distinguishable from their surroun-
ding based on their white color and round shape (Figure 34). Occasionally, blood vessels were
found on top or in close proximity to the gels, which macroscopically seemed to be independent
of HGF presence. As similarly reported [Deeken et al., 2011; Rennert et al., 2013], cellular
inﬁltration started at the edges of the implant (Figure 39), indicating an immune acceptance.
Under physiological circumstances, granulocytes, followed by monocytes/macrophages, are the
ﬁrst cells arriving at the wound site, contributing immensely to wound healing by phagocytosis
[Epstein et al., 1999]. The relatively low numbers of granulocytes, B-lymphocytes, macrophages
and mast cells (Figures 43, 44, 45, 46) suggested a minimal amount of inﬂammation after
seven days, which is in accordance to literature [Schroeder-Teﬀt et al., 1997]. In animals with
HGF-loaded collagen implants, neutrophil and eosinophil granulocytes were slightly increased
compared to HGF-free collagen implants (Figure 43), which might be attributed to HGF as a
promoter of neutrophil transmigration to sites of acute inﬂammation [Mine et al., 1998]. Higher
amounts of newly formed blood vessels were found proximal to HGF-loaded implants compared
to HGF-free implants (Figure 42), underlining the angiogenic potential of HGF [Bussolino
et al., 1992; Grant et al., 1993]. Neo-vascularization in animals implanted with HGF-free
collagen was similar to sham animals, indicating that collagen alone did not have an impact on
vessel formation. Similar to our results, delivery of FGF-1 in collagen scaﬀolds increased the
angiogenic potential, compared to controls in a full-thickness defect in rabbits [Pandit et al.,
1998]. The delivery of EGF or FGF-2 with collagen matrices promoted epithelialization as well
as diminished wound contraction compared to unloaded controls [Ono et al., 1999; Inoue et al.,
1998]. A pilot study in humans delivered evidence of HGF as a promoter of angiogenesis after
local application for seven days; after a total of three months, the micro-circulatory perfusion
of leg ulcers was increased in the majority of patients [Nayeri et al., 2002].
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After three weeks, all collagen gels were macroscopically still visible and blood vessels
seemed to be more pronounced than after the ﬁrst week, especially in the presence of HGF
(Figures 34, 42). Cellular inﬁltration, independent of HGF, was increased in all collagen scaﬀolds
compared to the ﬁrst week (Figure 39). Histological analysis revealed that inﬁltrating cells
were neither granulocytes nor macrophages, B-lymphocytes nor mast cells. Based on their
round, elongated morphology, we suspect them to be of mesenchymal origin, for instance
ﬁbroblasts, which are strongly involved in matrix remodeling and collagen synthesis in the
proliferating and remodeling phases of wound healing [Martin, 1997; Epstein et al., 1999].
Further evaluation is needed to conﬁrm this hypothesis. Compared to the ﬁrst week, the
amount of granulocytes (Figure 43) was slightly increased in all collagen-implanted animals,
independent of HGF. Their amount was still marginally higher than in sham animals, but this
response was not unusual since chronic inﬂammation is a phase with high amounts of neutrophil
and eosinophil granulocytes [Diegelmann and Evans, 2004]. Collagen may even serve as a
neutrophil chemotactic factor [Riley et al., 1988; Monboisse et al., 1991]. A recent study
provided evidence that collagen-based wound dressings promoted the migration of neutrophil
granulocytes into the wound bed [Elgharably et al., 2013]. In our study, signiﬁcantly elevated
numbers of monocytes/macrophages were found in animals implanted with HGF-free collagen
compared to sham animals after three weeks (Figure 45), which is a typical foreign body response
[Pandit et al., 1998]. Upon implantation of non-cross-linked collagen, increased numbers of
macrophages were observed after 14, 21 and 28 days [Ye et al., 2011; Rahmanian-Schwarz et al.,
2014]. In contrast, resolved response of macrophages at 14 days after collagen implantation
was reported [Rennert et al., 2013]. Interestingly, HGF-loaded collagen did not elicit a strong
monocyte/macrophage response (Figure 45), even though HGF was reported to be a paracrine
factor for monocytes [Galimi et al., 2001]. Physiologically, the presence of macrophages in the
wound bed indicates the transition of the inﬂammatory to the proliferative phase [Diegelmann
and Evans, 2004] and denotes the remodeling of the granulation tissue [Anderson et al., 2008].
Mast cells are partly responsible for the characteristics of inﬂammation, namely redness, heat,
swelling and pain [Artuc et al., 1999]. Upon activation, mast cells release histamine, heparin
and other mediators to stimulate neutrophil migration and permeabilize blood vessels [Metcalfe
et al., 1997]. Although higher amounts of mast cells were found in all collagen-implanted
animals than in sham animals (Figure 46), a direct correlation to neutrophil granulocytes was
not observable. The pronounced neo-vascularization in animals implanted with HGF-loaded
collagen compared to their HGF-devoid counterparts (Figure 42) can be explained with the
angiogenic potential of HGF [Silvagno et al., 1995; Morishita et al., 1999]. In agreement to our
ﬁndings, earlier onset of neo-vascularization compared to control groups was found after local
HGF injection into the wound in a ligament healing study in rabbits [Ueshima et al., 2011].
After twelve weeks, all collagen gels were still macroscopically detectable, albeit their shapes
were altered as they were degraded (Figure 34). There was no visible diﬀerence of the degrada-
tion rate between HGF-loaded and HGF-free collagen implants. The relatively slow degradation
rate of collagen was surprising, since non-cross-linked or unmodiﬁed collagen is generally de-
graded within several weeks in vivo [Anselme et al., 1990; Pachence, 1996; Helary et al., 2011;
Kagawa et al., 2012; Rahmanian-Schwarz et al., 2014]. However, the retention of about 80%
of non-cross-linked native collagen after four weeks of implantation was found [Ye et al., 2011].
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Cellular inﬁltration increased excessively in all collagen gels, independent of HGF, compared to
the ﬁrst and third week (Figure 39), penetrating almost the entire depth of the implant. This
shows the acceptance of the collagen gels by the surrounding tissues, comparable to literature
[Rennert et al., 2013] and suggests a continuous remodeling and degradation process over the
time of twelve weeks. Surprisingly, the amount of B-lymphocytes was highest after twelve
weeks and even signiﬁcantly higher in all collagen-implanted animals, independent of HGF,
compared to sham animals (Figure 44). To what extend lymphocytes play a role in wound
healing is still under investigation [Diegelmann and Evans, 2004]. The amount of macrophages
in all collagen-implanted animals was slightly higher compared to the previous time points and
compared to sham animals (Figure 45). This is contradictory to a recent study that reported
similar amounts of macrophages in collagen-implanted and control animals after 84 days in
vivo [Rahmanian-Schwarz et al., 2014]. The slight increase of mast cells, independent of HGF
(Figure 46), is a normal sign of late wound healing [Metcalfe et al., 1997]. After twelve weeks,
neo-vascularization was diminished in all animals, a natural feature of physiological wound
healing, as cell-devoid, collagen-intense scars are established [Shaw and Martin, 2009].
Overall, the immune responses towards HGF-free and HGF-loaded collagen were mostly
comparable to the ones of the sham animals at all time points which is in line with literature
[Pachence, 1996]. The generally low number of B-lymphocytes, except after twelve weeks,
indicated a very low immune reaction. The results point towards a slightly better tolerance of
HGF-loaded collagen gels than of their HGF-free counterparts. Our ﬁndings conﬁrm collagen
to be well tolerated as part of the natural environment, being low immunogenic and non-toxic.
Since collagen-based materials were established as wound dressings for clinical use in the late
1990s [Falanga and Sabolinski, 1999], our results attest their potential as drug delivery systems
for in vivo purposes.
4.4.2 Silk Fibroin Implants
One week after implantation, all silk ﬁbroin membranes were macroscopically clearly visible,
their round shape persisted, they were covered by a thin milky layer and blood vessels started
to form in close proximity (Figure 35). All silk ﬁbroin membranes, independent of HGF, were
surrounded by a dense network of cells, indicating an intensive immune response in the early
phase of acute inﬂammation (Figure 40). Higher amounts of granulocytes were present in
animals implanted with HGF-free silk ﬁbroin when compared to HGF-loaded membranes (Fi-
gure 43), suggesting a slightly better immune tolerance in the presence of HGF. This can also
be supported by the comparable amount of granulocytes in animals implanted with HGF-loaded
silk ﬁbroin membranes and sham animals. A marginal increase in monocytes/macrophages was
found in the presence of silk ﬁbroin membranes with HGF when compared to their HGF-devoid
counterparts (Figure 45) which is in accordance to literature [Etienne et al., 2009; Fredriksson
et al., 2009] However, HGF was described to be a promoter of macrophage migration in vitro
[Jiang et al., 1992; Beilmann et al., 1997]. Mast cell numbers were largely increased in all silk
ﬁbroin-implanted animals, independent of HGF, compared to sham animals (Figure 46) which
might indicate a moderate allergic response. As mast cells are known to release histamine-
containing granules, causing vasodilation and recruitment of inﬂammatory cells [Tang et al.,
1998; Artuc et al., 1999], this might explain the overall higher cell numbers surrounding the
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implants. In the early days of wound healing, lymphocytes invade the injured area [Martin, 1997].
Only animals implanted with HGF-free silk ﬁbroin showed signiﬁcantly increased amounts of B-
lymphocytes, while animals implanted with HGF-loaded silk ﬁbroin showed amounts comparable
to sham animals (Figure 44). The anti-inﬂammatory eﬀects of HGF were shown in diﬀerent
animal models of diseases (e.g. chronic kidney disease, inﬂammatory bowel disease, acute
colitis and airway hyper-responsiveness), suggesting that HGF may suppress a part of the
pro-inﬂammatory process [Gong, 2006] which might be the case in our study. The strong
neo-vascularization in HGF-implanted animals (Figure 42) might be triggered by HGF since
its pro-angiogenic eﬀects in vivo were described quite early [Grant et al., 1993]. In addition,
HGF stimulates the motility of endothelial cells [Bussolino et al., 1992], expression of VEGF
in keratinocytes [Gille et al., 1998] as well as the synthesis of platelet-activating factor by
macrophages [Camussi et al., 1997], all playing a part in neo-vascularization.
After three weeks, the thin milky layer around the silk ﬁbroin implants was still visible and
neo-vascularization near the HGF-loaded silk ﬁbroin implants was increased (Figure 35). All
silk ﬁbroin membranes were starting to be encapsulated as described earlier [Bennett, 1988;
Meinel et al., 2005]. Signiﬁcantly higher amounts of granulocytes were found in all silk ﬁbroin-
implanted animals, independent of HGF, compared to sham animals (Figure 43). These and
the slightly elevated numbers of monocytes/macrophages, especially in the presence of HGF
(Figure 45), indicate chronic inﬂammation which can persist for up to two weeks [Diegelmann
and Evans, 2004; Anderson et al., 2008]. Monocytes/macrophages are largely involved in ﬁbrous
capsule formation through their adherence to the implant surface and fusion to form foreign
body giant cells. Similar to our ﬁndings, studies reported the presence of macrophages around
silk ﬁbroin scaﬀolds after two and four weeks in vivo [Wang et al., 2008; Etienne et al., 2009].
B-lymphocyte numbers subsided in all animals implanted with silk ﬁbroin and were similar to
sham animals (Figure 44), which is in line with literature [Dal Pra et al., 2005]. Signiﬁcantly
higher amounts of mast cells in animals implanted with HGF-loaded silk ﬁbroin compared to
HGF-free implants (Figure 46), can be attributed to HGF as a potential recruitment factor for
mast cells [Bevan et al., 2004]. As mast cells enhance vasodilation [Metcalfe et al., 1997], they
possibly inﬂuence neo-vascularization through the secretion of heparin and VEGF [Artuc et al.,
1999]. The pro-angiogenic potential of HGF [Bussolino et al., 1992; Grant et al., 1993] might
explain the strong neo-vascularization in animals with HGF-loaded implants (Figure 42). As
vascularization facilitates cell migration into the tissues [Tonnesen et al., 2000], it might also
account for the generally higher amounts of macrophages and mast cells.
After twelve weeks, the milky layer persisted around all silk ﬁbroin membranes (Figure 35).
This dense cell layer seemed to be more compact and thinner after twelve weeks than after
three weeks, suggesting progressed encapsulation which was described earlier [Meinel et al.,
2005; Wang et al., 2008; Cao and Wang, 2009; Moisenovich et al., 2012]. It can persist
lifelong and depends on various factors, such as the site of implantation, size, geometry and
surface topography of the implant [Altman et al., 2003; Anderson et al., 2008]. The amounts
of granulocytes in animals implanted with HGF-free membranes were similarly high than after
three weeks and signiﬁcantly higher than in HGF-loaded membranes (Figure 43). The prolonged
and strong presence of granulocytes hints at an extended inﬂammatory phase [Anderson et al.,
2008]. In contrast, the amount of granulocytes proximal to HGF-loaded membranes dropped
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largely and was similar to sham animals which corresponds to an earlier study [Etienne et al.,
2009]. This group prepared 3D silk ﬁbroin gels that have an altered degradability and biological
behavior [Vepari and Kaplan, 2007] compared to membranes, which, in turn, can inﬂuence the
degree of the immune response. In unhampered wound healing, granulocytes are phagocytozed
by macrophages in the remodeling phase to give way for ﬁbroblasts [Gurtner et al., 2008]
which might be the case for animals with HGF-loaded silk ﬁbroin implants. The numbers
of monocytes/macrophages increased considerably between the third and twelfth week in all
silk ﬁbroin-implanted animals (Figure 45), indicating a (late) transition between inﬂammatory
and proliferative phase [Diegelmann and Evans, 2004]. The presence of mast cells was similar
between both implant groups and signiﬁcantly higher compared to sham animals (Figure 46).
It is possible that the allergic responses towards silk ﬁbroin remained. After twelve weeks, neo-
vascularization decreased, which is in accordance to physiological wound healing [Shaw and
Martin, 2009].All silk ﬁbroin membranes remained unpenetrated at all time points. The slow
bio-degradation and absorption of silk as suture materials was already known in the late 1980s
[Bennett, 1988] and was lately reported for silk ﬁbroin scaﬀolds by several groups [Dal Pra
et al., 2005; Lee et al., 2012; Moisenovich et al., 2012].
All in all, HGF-loaded and HGF-free silk ﬁbroin membranes were tolerated moderately,
accounting for the formation of a ﬁbrous capsule around all implants, independent of HGF,
after about three weeks after implantation. The wound healing cascade was disturbed at
several stages, especially regarding the transition from the acute to the chronic inﬂammatory
phase which usually takes place around the ﬁrst weeks after implantation. It seems as if HGF-
loaded silk ﬁbroin membranes were tolerated better than their HGF-free counterparts, based on
the high amount of neo-vascularization, the lower amounts of granulocytes after twelve weeks,
as well as the overall low level of B-lymphocytes.
4.4.3 Comparison of Collagen and Silk Fibroin Implants
Overall, cell responses towards silk ﬁbroin±HGF were stronger than towards collagen±HGF.
Firstly, the amount of neutrophil and eosinophil granulocytes was highest in silk ﬁbroin-implan-
ted animals, independent of HGF, at almost all time points, in particular after the third week
(Figure 43). In addition, HGF-free silk ﬁbroin membranes elicited signiﬁcantly stronger granulo-
cyte responses compared to HGF-free collagen at all time points. In contrast to our ﬁndings,
silk ﬁbroin ﬁlms produced comparable results to non-cross-linked lyophilized irradiated porcine
dermis by promoting wound healing in a full-thickness skin wound model after 21 days [Sugihara
et al., 2000]. Likewise, an equivalent low inﬂammatory response towards silk ﬁbroin (modiﬁed
with the tri-peptide L-arginine-glycine-L-aspartic acid (RGD)) and cross-linked collagen was
found after six weeks, while polylactic acid elicited the highest inﬂammatory response [Meinel
et al., 2005]. The modiﬁcation with RGD most likely takes part in decreasing the immune
response. Secondly, collagen gels, independent of HGF, were quickly invaded by cells, while silk
ﬁbroin membranes, independent of HGF, elicited a foreign body response (Figures 39, 40). To
reduce the foreign body response, researchers suggested coatings with collagen type I/hyaluronic
acid multilayer ﬁlms for in vivo studies [Hsieh et al., 2014]. Collagen gel degradation was
observable with ongoing time, whereas all silk ﬁbroin membranes were encapsulated, starting
between the ﬁrst and third week. Thirdly, silk ﬁbroin membranes, independent of HGF, elicited
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higher responses of mast cells than collagen gels (Figure 46), indicating a possible allergic
reaction. Especially after twelve weeks, the amount of mast cells in animals with silk ﬁbroin
implants was about double the amount of mast cells in animals with collagen implants. It might
be of interest to elucidate the presence of other allergy-related cell types, such as regulatory T-
lymphocytes or basophil granulocytes. The somewhat disparate results regarding B-lymphocytes
for collagen and silk ﬁbroin implants, independent of HGF, make it diﬃcult to correctly rate
the performance of the biomaterials (Figure 44). A closer look at the various subsets of B-
lymphocytes will shed further light on humoral immunity.
One similarity between HGF-loaded collagen and silk ﬁbroin was the amount of neo-
vascularization after the ﬁrst week (Figure 42)
Regarding immune tolerance and (bio)compatibility, collagen implants performed slightly
better than silk ﬁbroin implants, independent of HGF. HGF-loaded silk ﬁbroin implants were
superior to their HGF-devoid counterparts because of their strong promotion of neo-vasculari-
zation. However, all silk ﬁbroin membranes delayed the phases of physiological wound healing
to some extend.
Diﬀerent ﬁelds of TE have reported the superiority of silk ﬁbroin over other materials and
its suitability has been investigated. For example, silk ﬁbroin hydrogels promoted the healing
of critical size cancellous defects better than PLGA [Fini et al., 2005] and silk ﬁbroin screws
compared favorably to current screws made of PLGA used for fracture ﬁxation, based on their
self-tapping characteristics (the screw is able to thread its own hole while it is driven into
the material) [Perrone et al., 2014]. The beneﬁts of silk ﬁbroin matrices over e.g. poly(L-
lactic acid), polyethylene terephthalate and even collagen are seen in its ability to match the
mechanical properties and fatigue performance of native human anterior cruciate ligaments
[Altman et al., 2002].
Taken together, collagen and silk ﬁbroin are suitable delivery vehicles for HGF in vivo. To
our knowledge, this is the ﬁrst study elucidating silk ﬁbroin membranes from transgenic silk
worms to deliver HGF in vivo. Further studies are needed to investigate safety, eﬃcacy and
feasibility of HGF-loaded biomaterials to be used as wound dressings for chronic wounds or
burns.
4.5 In vivo Recruitment of Mesenchymal Stem Cells
Mobilizing endogenous stem cells to injured tissue is a quite novel alternative to stem cell
therapies. Lately, scientists are developing strategies to mobilize the patient's own MSC to the
sites of injury by implanting growth factor-loaded scaﬀolds or directly delivering biomolecules.
By this, current challenges in MSC therapies, such as safety, quality control, clinical grade
production and the question of using autologous versus allogenic MSC can be circumvented
[Wang et al., 2012].
MSC migration, or homing, is deﬁned as the arrest of MSCs within the vasculature of a
tissue followed by transmigration across the endothelium [Karp and Leng Teo, 2009]. In vivo,
homing is a ﬁnely tuned and complex interplay, involving numerous signaling and adhesion
molecules and diﬀerent types of (stem) cells. To date, several questions remain unanswered
[Lapidot and Petit, 2002; Chen et al., 2010].
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Under physiological conditions, MSC circulate in the peripheral blood only in low amounts
[He et al., 2007]; however, their numbers are increased upon injuries, such as large skin damage
[Mansilla et al., 2006], skeletal muscle injury [Ramirez, 2006], hypoxia [Rochefort et al., 2006]
or bone fractures [Alm et al., 2010]. As most laboratories are focused on investigating the
homing capacity of (tracked) transplanted MSC [Thevenot et al., 2010; Purcell et al., 2012;
Hu et al., 2013], little is known on the homing behavior of endogenous MSC in vivo. Recently,
the importance of active TGF-β either released from mechanically injured arteries or injected
intravenously on MSC mobilization was highlighted [Wan et al., 2012]. MSC recruitment
into the peripheral blood and to the sites of injury was evaluated by ﬂow cytometry analysis
for MSC markers in blood samples (Sca1+, CD29+, CD11b−, CD45− were considered MSC),
immunoﬂuorescent stainings (nestin, Sca1, CD29, CD11b and TGFβ1), immunohistochemical
stainings for active TGFβ expression as well as TGFβ ELISA for levels of total and active
TGFβ from murine plasma [Wan et al., 2012]. Peptide sequence-conjugated polycarprolactone
electrospun meshes selectively recruited MSC in a micro-fracture cartilage defect model. The
results were obtained from immunoﬂuorescence stainings and ﬂow cytometric analysis for CD44,
CD68, CD90 and CD105 [Shao et al., 2012].
Unfortunately, the lack of one unique MSC marker [Caplan and Correa, 2011; Boxall and
Jones, 2012] hampers observations and complicates analysis. In addition, the immunopheno-
type of circulating MSC may not completely correspond to the one of MSC expanded ex vivo
[Eggenhofer et al., 2014]. Nevertheless, we carried out immunoﬂuorescent stainings for c-Met
and nucleostemin, two potential markers for murine and human MSC [Naldini et al., 1991; Bad-
doo et al., 2003; Kaﬁenah et al., 2006]. Expression of nucleostemin was reported for embryonic
stem cells and other stem-cell enriched populations, but decreased rapidly upon diﬀerentiation
[Tsai, 2002]. C-Met expression is found in specialized cell types such as hepatocytes, ker-
atinocytes [Birchmeier and Gherardi, 1998; McCawley et al., 1998], endothelial cells [Ishizawa
et al., 2004] or macrophages [Moransard et al., 2009]; these cells should therefore be negative
for nucleostemin expression. Both antibodies were coupled to diﬀerent ﬂuorochromes (FITC
and Northern Lights 557) and DAPI was used for nuclei staining. For the purpose of this study,
all cells simultaneously expressing c-Met (green) and nucleostemin (red) were termed double-
colored cells and were considered most likely to be MSC or at least stem cell-related. Possibly
not all double-colored cells were indeed true MSC, albeit the combination of the two antibodies
ruled out other (speciﬁed) cell types present in the surrounding tissue. Furthermore, not all of
those cells might be derived from the bone marrow, but from hair follicles, the interfollicular
epidermis or adipose tissue [Andreas et al., 2014; Eggenhofer et al., 2014]. Quantiﬁcation and
evaluation were carried out after one, three and twelve weeks of implantation by three diﬀerent
investigators in a blinded fashion. Conducting further analysis such as ﬂow cytometry, poly-
merase chain reaction, histology or Western blots could additionally support the notion of the
presence and origin of MSC.
Delivery vehicles are the best way to administer chemokines, because of their short half-
lives, cleavage through proteases and rapid diﬀusion [Andreas et al., 2014]. The half-life time
of injected HGF was reported to be between three and ﬁve minutes [Appasamy et al., 1993;
Kawaida et al., 1994]. While a few other biomaterials have been elicited for in vivo MSC capture
or entrapment [Shao et al., 2012], non-cross-linked collagen gels and silk ﬁbroin membranes
69
4 DISCUSSION
from transgenic silkworms have not yet been investigated. To the best of our knowledge, this
study presents for the ﬁrst time the eﬀect of HGF-loaded biomaterials on the recruitment of
MSC in vivo.
While the results for HGF-loaded silk ﬁbroin membranes were consistent throughout the
experiment, the results for HGF-loaded collagen implants was not. At all time points, the
amount of double-colored cells for HGF-loaded silk ﬁbroin implants was (signiﬁcantly) higher
than for their HGF-free counterparts and even increased continuously over time in the presence
of HGF (Figure 48). Even though the implantation of HGF-loaded collagen gels resulted in
signiﬁcantly higher double-colored cells compared to HGF-free collagen after one and twelve
weeks (Figure 48 A, C), surprisingly, after three weeks, almost no cells were found proximal
to collagen gels, independent of HGF (Figure 48 B). It is diﬃcult to interpret these disparate
results, since the superiority of HGF was clearly shown at all other time points and for both
materials. Since a recent review described collagen (in various forms) as a suitable carrier for
biomolecules for attracting endogenous (stem) cells [Andreas et al., 2014], we propose that
increasing the sample size will probably lead to similar results as the rest of the conditions.
Nonetheless, except for this discrepancy, our ﬁndings are in conformity with literature as HGF
is considered a chemoattractant for (endogenous) MSC [Neuss et al., 2004; Lau et al., 2009;
Chen et al., 2010]. In addition, recent reviews identiﬁed HGF as a promising chemokine in TE
and particularly regarding stem cell recruitment [Lee et al., 2010b; Vanden Berg-Foels, 2013].
Concluding, we can attest the suitability of collagen and silk ﬁbroin implants to deliver
biomolecules as described earlier [Schneider et al., 2009; Naderi et al., 2011; Demidova-Rice
et al., 2012; Meinel and Kaplan, 2012]. As we neither observed any highly unfavorable eﬀects
from any of the implants nor regarding inﬂammation, these results indicate that both HGF-
loaded biomaterials could, in fact, mobilize MSC-like cells to sites of injury. Future studies are
needed to support our ﬁndings and elucidate MSC homing behavior towards HGF released from
diﬀerent biomaterials in models of wound repair and burns.
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5 Conclusion and Prospect
This thesis was carried out with the objective of investigating the inﬂuence of HGF released
from biomaterial scaﬀolds on MSC recruitment in vitro and in vivo. The questions addressed
in the present study were answered as follows:
1. HGF-incorporation into collagen gels, ﬁbrin gels and silk ﬁbroin membranes and its release
in vitro
◆ HGF was successfully incorporated into collagen and ﬁbrin gels during polymeri-
zation. A transgenic silk worm producing HGF-loaded ﬁbroin was successfully gene-
rated for this project by Spintec Engineering.◆ HGF was released from all biomaterials in a burst-like fashion during the ﬁrst eight
hours; then in a gradual way over two to seven days. After seven days, approximately
half of the amount of HGF was still present in the collagen and ﬁbrin gels. The
total concentration of HGF released from the silk ﬁbroin membranes was relatively
low, but elicited MSC responses in vitro.
2. MSC mobilization in vitro
◆ HGF-loaded biomaterials mobilized and attracted MSC in vitro◆ The HGF-receptor c-Met was proven to be involved in MSC motility in vitro
3. In vivo responses towards HGF-loaded and HGF-free implants
◆ Collagen gels were tolerated well and without any adverse eﬀects. Silk ﬁbroin mem-
branes elicited a mild to moderate immune reaction. Both biomaterials were stable
at least for twelve weeks. Fibrin implants were degraded after six to eight days,
independent of HGF presence.◆ After one week, HGF-loaded collagen and silk ﬁbroin initiated neo-vascularization.
Independent of HGF, collagen was invaded by cells, whereas silk ﬁbroin membranes
were covered by a dense network of cells, independent of HGF. After three weeks,
granulocyte attraction was enhanced by HGF-loaded collagen, while higher amounts
of mast cells were attracted by HGF-loaded silk ﬁbroin. After twelve weeks, dense
ﬁbrotic capsules were formed around HGF-loaded and HGF-free silk ﬁbroin. The
degradation of collagen implants, independent of HGF, continued.◆ HGF-loaded collagen and silk ﬁbroin elicited endogenous MSC migration in the
mouse, especially after one week of implantation, corresponding to the inﬂammatory
phase of wound healing
Essentially, the data obtained in this project support the hypothesis of MSC migration towards
HGF released from collagen gels, ﬁbrin gels and silk ﬁbroin membranes in vitro. In vivo,
endogenous MSC were recruited towards HGF-loaded collagen gels and HGF-loaded silk ﬁbroin
membranes which could improve wound healing.
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Further investigations might focus on optimizing HGF coupling, thereby improving HGF
release kinetics to suit particular clinical needs. Several strategies, such as heparin immobili-
zation, covalent coupling of therapeutics or surface modiﬁcation with RGD were proven eligible.
Degradation behavior is closely interconnected to release kinetics and can be tailored with vari-
ous physico-chemical processing methods. While collagen is most often cross-linked to prevent
its fast degradation, crystallinity or porosity of silk ﬁbroin is regulated to accelerate its degra-
dation. For instance, a (loose) network of silk ﬁbroin ﬁbers is populated by cells more easily
than a ﬁrm membrane, thus promoting degradation; at the same time, proteases can cleave
HGF from larger areas more eﬀectively. Silk ﬁbroin hydrogels are promising due to their conve-
nient applicability either topically or minimally invasive through injections. Their gel-like nature
facilitates cellular in-growth which, in turn, promotes degradation. Combining collagen and silk
ﬁbroin into one ﬂexible wound coverage, thereby simultaneously exploiting their advantages,
could open up new possibilities in wound treatment. For example, the extracellular matrix-like
environment of collagen and the tailorable mechanical properties of silk ﬁbroin could interact
with and cover the local tissue to promote the healing of chronic wounds or burns.
The results of ﬁbrin in combination with HGF on the mobilization of MSC in vitro were
promising and investigations of HGF-loaded ﬁbrin implants regarding HGF release and MSC
recruitment should be pursued. Previous studies suggested the addition of aprotinin or tranex-
amic acid to prolong ﬁbrin stability in vitro and in vivo; this might be a feasible approach to
test ﬁbrin as a temporary wound dressing.
In the future, one project will encompass a large animal study to investigate the suitability of
HGF-loaded collagen gels and silk ﬁbroin membranes regarding their MSC recruitment eﬃcacy
when used as wound dressings for chronic wounds or burns. A porcine model was chosen due
to the pig's anatomical and physiological similarity to human skin. With this, the behavior
of endogenous MSC and other immune cells in correspondence to HGF/c-Met signaling could
be investigated in more detail. Looking ahead, clinical trials are inevitable in order to assess
safety and eﬃcacy of HGF-delivery systems as wound dressings for human use. In the future,
promoting wound healing through the application of HGF-loaded scaﬀolds might become an
alternative for patients in need of immediate wound care.
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